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LIST OF ABBREVIATIONS 
 
3D CRT three-dimensional conformal radiation therapy 
A adenine 
AACR American Association of Cancer Research 
ACS active symptom control 
AE1/AE3 pan cytokeratin antybody AE1/AE3 
AJCC American Joint Committee on Cancer  
AKT Protein kinase B 
ALT alternative lengthening of telomeres  
AP1 Activator Protein 1 
ARID2 AT-Rich Interaction Domain 2 
ASSI Argininosuccinate synthase 1 
ATP Adenosine triphosphate 
ATRX Alpha Thalassemia/Mental Retardation Syndrome X-Linked 
ATS American Thoracic Society 
AUT Austia 
BAP-1 BRCA1-associated protein-1  
BAP1-TPDS BRCA1-associated protein-1 tumor predisposition syndrome   
BARD1 BRCA1-associated RING domain protein 
Ber-EP4 anty-Epithelial cell adhesion molecule-antibody Ber-EP4 
BG8 Blood group 8 
BMM biphasic malignant mesothelioma 
BRIP1 BRCA1 Interacting Protein C-Terminal Helicase 1 
BSC best supportive care 
BTS British Thoracic Society  
C cytosine 
c. codone 
CANT1 Calcium Activated Nucleotidase 1 
CAR Chimeric antigen receptor 
CD15 cluster of differentiation 15 
CD79B B-Cell Antigen Receptor Complex-Associated Protein Beta Chain 
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CD80 cluster of differentiation 80 
CDKN2A cyclin-dependent kinase Inhibitor 2A 
cDNA complementary DNA 
CEA Carcinoembryonic antigen  
CHT chemotherapy 
CI confidence intervall 
CK cytokeratin 
CK 5/6 cytokeratin 5/6 
cKIT  KIT proto-oncogene, receptor tyrosine kinase 
CRO Croatia 
CRP C Reactive Protein 
CT computed tomography 
CTLA4 cytotoxic T-lymphocyte-associated protein 4 
D2-40 monoclonal anti-podoplanin-antibody D2-40 
DAXX Death Domain Associated Protein 
DNA deoxyribonucleic acid 
dsDNA double-strand DNA 
E2F1 E2F Transcription Factor 1 
ECOG PS Eastern Cooperative Oncology Group Scale of Performance Status 
EGFR epidermal growth factor receptor 
EMM epithelioid malignant mesothelioma 
EORTC European Organisation for Research and Treatment of Cancer 
ePD extended pleurectomy/decortication 
EPP extrapleural pulmonectomy  
ERS European Respiratory Society 
ETS E-twenty-six 
EURACAN European Network for Rare Adult Solid Cancers 
EZH2 Enhancer of zeste homolog 2 
FAK Focal adhesion kinase 
FAT4 FAT Atypical Cadherin 4 
FDG  fluorodeoxyglucose 
FFPE Formalin fixed paraffin embedded 
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FISH fluorescent in situ hybridization 
G guanine 
GABPA/B GA Binding Protein Transcription Factor Subunit Alpha/Beta 
GATA3 GATA Binding Protein 3 
GCDFP15 Gross cystic disease fluid protein 15 
Gly glycine 
Gy Grey 
HE hematoxylin eosin 
HIF1 Hypoxia Inducible Factor 
HMGB-1 High mobility group box 1 protein 
HPF high power field 
HR hazard ratio 
HSV1716 Herpes simplex virus 1716 
IASLC International Association for the Study of Lung Cancer  
IC50 half maximal inhibitory concentration 
IFN-β interferon beta 
IMIG International Mesothelioma Interest Group 
IMRT Intensity-modulated radiotherapy 
IQR interquartile range 
KIBRA Kidney and brain protein 
KPS Karnofsky performance status scale 
LADC lung adenocarcinoma 
LATS2 Large Tumor Suppressor Kinase 2 
Leu-M1 monoclonal anti-CD15-antibody Leu-M1 
M/N score mitosis-necrosis score 
MARS Mesothelioma and Radical Surgery 
MCR macroscopic complete resection 
MDM2 Mouse Double Minute 2, 
MLLT3 MLLT3 Super Elongation Complex Subunit 
MM malignant mesothelioma 
MMT Multimodality treatment  
MOB1 Mps One Binder Kinase Activator-Like 1B  
DOI:10.14753/SE.2020.2421
 8 
MOC31 anty-Epithelial cell adhesion molecule-antibody MOC31 
MPM malignant pleural mesothelioma 
mRNA messenger RNA 
MST1/2 Mammalian STE20-Like Protein Kinase 1/2 
MTAP Methylthioadenosine Phosphorylase 
mTOR  mammalian target of rapamycin 
mut mutant 
MYC V-Myc Avian Myelocytomatosis Viral Oncogene Homolog 
NA not available 
NF2 Neurofibromatosis type 2 
OD optical density 
OR overall risk 
OS overall survival 
p. protein amino acid 
p16 cyclin-dependent kinase inhibitor 2A 
p40 anty-deltaNp63-antibody 
PARP Poly (ADP-ribose) polymerase 
PAX2 Paired box gene 2 
PAX8 Paired box gene 8 
PBRM1 Polybromo 1 
PBS Phosphate-buffered saline 
PCR polymerase chain reaction 
PD pleurectomy/decortication 
PD(L)1 programmed death (ligand) 1 
PET-CT Positron emission tomography–computed tomography  
PFS progressio-free survival 
PI3K Phosphoinositide 3-kinase ( 
POT1 Protection Of Telomeres 1 
pRb retinoblastoma protein  
PSEN1 presenilin-1 
PTCH1 Patched 1 
PTPRD Protein Tyrosine Phosphatase Receptor Type D 
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qRT-PCR quantitative reverse transcription polymerase chain reaction 
RAD51 RAD51 Recombinase 
RAP1 Repressor/Activator Protein 1 Homolog 
RNA ribonucleic acid 
RPL41 Ribosomal Protein L41 
RT raditherapy 
SAV1 Salvador Family WW Domain Containing Protein 1 
SE standard error 
SETD2 SET Domain Containing 2, Histone Lysine Methyltransferase 
SETDB1 SET Domain Bifurcated Histone Lysine Methyltransferase 1 
SLO Slovenia 
SMM sarcomatoid malignant mesothelioma 
SMYD3 SET And MYND Domain Containing 3 
SNP single nucleotid polymorphism 
SP1 Specificity Protein 1 
SQCC squamous cell carcinoma 
SRB Sulforhodamine B 
T thymine 
TAZ Tafazzin 
TCGA The Cancer Genome Atlas 
TEAD transcription-enhancer activator domain transcripition factor 
TEK TEK Receptor Tyrosine Kinase 
TERC Telomerase RNA Component 
TERT Telomerase Reverse Transcriptase 
TERTp TERT promoter 
THOR TERT hypermethylation oncological region  
TIN2 TRF interacting protein 2 
TNM tumor, nodes and metastases 
TP53 Tumor Protein P53 
TPP1 TINT1/PTOP/PIP1 





TTF-1 thyroid transcription factor 1 
UICC Union for International Cancer Control  
VATS video-assisted thoracoscopy  
VGFR Vascular endothelial growth factor  
WBC white blood cell count 
WHO World Health Organisation 
wt wild-type 
WT-1 Wilms' tumour 1 
WWTR1 WW Domain Containing Transcription Regulator 1 





1.1 Epidemiology of malignant pleural mesothelioma 
 
Malignant mesothelioma (MM) is a rare malignancy arising from the mesothelial cells 
of serous membranes such as the pleura, peritoneum[1], pericardium[2], tunica vaginalis 
of the testis[3] and ovarial surface epithelium[4]. Malignant pleural mesothelioma 
(MPM) is the most common form of malignant mesothelioma accounting for 80-85% of 
the cases [5]. 
According to the World Health Organisation (WHO) mortality database 92,253 
malignant mesothelioma deaths were reported in the period between 1994 and 2008 
from 83 countries across the world. Worldwide, crude and age-adjusted mortality rates 
were 6.2 and 4.9 deaths per million population, respectively, the latter showing a yearly 
increase of 5.37%. During the studied time period malignant mesothelioma associated 
deaths occurred more frequently in the high-income countries of the Americas and 
Europe [6]. 
MPM’s incidence varies substantially across the world. MPM’s age standardized-rate 
incidence was 1.93 per 100,000 among men, and 0.41 among women in the United 
States. Standardized-rate incidences were 3.5 among men and 1.25 per 100,000 among 
men and women in Italy [7], while among males in Great Britain it was 3.4/100,000, 
2.3/100,000 in France, and 3.2/100,000 in the Netherlands [8]. Lower MPM incidence 
rates are reported n Central and Eastern Europe, 1.84 in Croatia and 1 per 100,000 men 
in Austria [9]. 
MPM incidence and mortality not only shows spatial variations, but also changes over 
time. Number of MPM associated deaths has been rising during the 20th century due to 
the rising production and consumption of asbestos. In North America and Western 
Europe the rise in incidence is expected to level out in the near future and then decrease. 
During the first decade of the 2000s Sweden already experienced a decrease in the 
number of MPM cases thanks to early adaptation of strict regulation of asbestos 
handling [10, 11]. In other countries like Italy, Netherlands and France show stagnant 
MPM mortality rates, which are expected to decrease in the near future [12, 13]. In 
contrast, Eastern European countries are still witnessing an increase in the burden of 
asbestos related carcinogenesis [14]. 80% of the world’s population still lives in 
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countries where there is no ban on asbestos (Figure 1) [15, 16] which causes a 
continued increase of MPM incidence worldwide [8]. 
 
 
Figure 1. The use and production of asbestos is currently banned in 67 countries. Early 
bans were introduced in Western Europe before 2000 (dark green). Several countries 
have implemented such measures only after 2000 (light green). The author’s drawing 
based on data from [17, 18]. 
 
Due to the long latency period after exposure MPM is most commonly diagnosed in 
patients older than 65 years [14]. 2% of all MPM patients are younger than 40 years, 
and they have a significantly better overall survival among all three main histological 
subtype, than those older than 40 (11 months vs. 8 months) [19].  
MPM is approximately four times more common among males than females, which 
might be explained by males traditionally working in positions with higher risk of 
occupational asbestos exposure [19]. The French National Mesothelioma Surveillance 
Program calculated the MPM risk fraction attributable to occupational exposure for both 
genders, and estimated it to be 83.2% (95% CI 76.8-89.6) for men, while only 38.4% 
(95% CI 26.8-50.0) for women [20]. Enviromental exposure, however is a higher 
burden for women, the male-to-female ratio being approximately 1, and MPM risk 
associated with environmental exposure in women being 38.7% and 20% in men [21]. 
Women with mesothelioma have been reported to have a significantly longer survival 
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compared to men, a phenomenon also in part attributable to differences in the doses of 
asbestos exposure [22]. 
 
1.1.1 Asbestos exposure and malignant pleural mesothelioma 
 
Of all MPM cases, approximately 80% are estimated to be linked to inhalation of 
asbestos fibers (Figure 2) [23], while only 10% of those substantially exposed to 
asbestos develop MPM [24]. Asbestos carcinogenesis is linked to DNA damage caused 
by direct mechanical interference of asbestos fibers whit chromosomes, as well as by 
reactive oxygen and nitrogen species secreted by mesothelial cells and macrophages 
[25]. The HMGB-1 mediated necrosis and chronic inflammation induced by the 
depositions of asbestos fibers also plays a role in the development of MPM [26]. 
 
 
Figure 2. Asbestos bodies, also known as ferruginous bodies are dumbbell-shaped, 
thin structures covered by a coat of proteins and iron-containing 
mucopolysacchirdes, that stain blue with Prussian blue staining [27]. Reprinted 




Ecological correlations have been shown to be robust between a country’s historical 
asbestos consumption given in kg per person per year and its age-adjusted annual MM 
and MPM mortality rates [29]. 
Crocidolite, amosite and chrysotile are the three types of asbestos associated with the 
induction of MPM, the ratio of exposure specific risk of MPM from the three principal 
types of asbestos is estimated to be 500:100:1 [30]. Eternit workers and wives were 
typically exposed to a mixture of crocidolite and chrysotile, while railway stock workers 
were predominantly exposed to crocidolite, and amosite factory workers to amosite 
[31]. 
Regional clustering of MPM cases was observed within several Western European 
countries [32]. The hotspots were identified most commonly in the vicinity of harbors 
with oil refieneries or shipyards due to historical asbestos use in shipbuilding and repair 
(eg. South-East England [33], Genoa and Trieste, Italy [34]), asbestos mines and 
asbestos-cement industries (eg. Casale Monferrato, Italy ) or near railway carriage 
construction and repair sites (eg.Veneto, Italy) [35].  Men between the ages of 40 and 74 
years in Scotland and England had an age standardized MPM incidence rate of 8.8 and 
8.0 per 100,000, in the Trieste and Genova region of Italy 17.2 and 14.4 per 100,000 
persons, respectively, while for the remaining European countries an incidence of 0.6- 
4.2 per 100,000 was observed in the time period beween 1991 and 1995 [24].  
A study carried out by the French National Mesothelioma Program identified industries 
associated with the highest risk for MPM. French men working in shipbuilding and 
repair had more than 9 times higher risk (OR=9.3, 95% CI: 5.20-16.06) for developing 
MPM compared to those never having worked in asbestos related occupations. Among 
others, the men working in the manufacturing of astbestos products, of metal 
constructions, plumbers, construction workers, electrical wiremen and those working in 
railroad equipment production were also at substantially higher risk for MPM [36]. 
Patients in household contact with workers exposed to asbestos also have an elevated 
risk for pleural disease [37].  
A large pooled analysis of cohort studies including workers with occupational exposure 
and individuals with environmental asbestos exposure found the median age at the time 
of first exposure to be in the early- to mid-20s, and the median length of exposure to be 
3.75 years (IQR 0.7-18.2). The median time between exposure and the diagnosis of 
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MPM was 38.4 years (IQR 31.3-45.3). The risk of developing MPM increased for 45 
years after exposure, after that the increase in risk appeared to level out [31]. 
 
1.1.2 Non-asbestos related MPM 
 
Approximately 20% of all MPM cases occur without asbestos exposure. The role of 
potential alternative risk factors remains unclear. Non-asbestos minerals that have a 
similar fibrous form and high biopersistence to that of commercial asbestos varieties 
also have carcinogenic potential, especially erionite [38]. An in vivo experiment showed 
that carbon nanotubules beyond the threshold length of 4 µm caused acute pleural 
inflammation, that is considered an early event in MPM carcinogenesis [39]. Exposure 
to ionizing radiation [40], and Simian virus 40-like virus infection [41] have been 
proposed as risk factors in a subset of MPM patients, however, their role needs further 
verification [42]. 
 
1.1.3 Genetic predisposition to MPM 
 
The germline mutations in the gene encoding BRCA1-associated protein-1 (BAP-1) 
have recently been described as a predisposing genetic factor of MPM [43]. This high 
penetrance germline mutation causes a newly recognized cancer syndrome, namely the 
BAP-1 tumor predisposition syndrome (BAP1-TPDS), which is characterized by the 
development of distinct tumor types by the age of 55 years [44]. Carriers show an 
increased risk to develop peritoneal or pleural mesothelioma, but are also predisposed to 
other tumor types, such as atypical Spitz tumor [45, 46], cutaneous or uveal melanoma 
[47], renal cell carcinoma [48], breast cancer, basal cell carcinoma [49] and less 
frequently to further malignancies [50, 51]. The MM patients carrying these germline 
mutations are typically younger than those with sporadic MM, more than 60% of them 
are female, and they have a significantly longer overall survival compared to all MM 
patients [52, 53]. 
A recent study suggests that germline mutations of the CDKN2A gene predispose not 
only to malignant melanoma, but also to MPM. However, the associated potential 
cancer syndrome needs further investigation, since there is only one identified carrier of 
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the germline CDKN2A mutation (c.301G > T, p.Gly101Trp) who developed malignant 
cutaneous melanoma and has a history of both melanoma and MPM in her family [54].  
 
1.2 Clinical diagnosis and staging of MPM 
 
The diagnosis of MPM is often challenging, as symptoms present at a late stage of the 
disease progression, and are non-specific [55]. The most common symptoms are 
dyspnoe and chest pain. Dyspnoe is caused by a typically unilateral pleural effusion. 
Chest pain might be diffuse and dull, or less often of pleuritic nature [56]. Other patients 
present with weight loss, fatigue, or sweats. Local spread of the tumor into mediastinal 
structures can cause dysphagia, superior vena cava syndrome or recurrent laryngeal 
nerve palsy [57]. 
The diagnostic pathway for MPM proposed by the British Thoracic Society (BTS) 
includes chest radiography as first line imaging modality for patients with symptoms 
suspicious for MPM [58]. On radiographs, unilateral pleural effusions are present in 
94% of the cases. Further findings typical for MPM include a diffuse thickening of the 
pleura, which might cause a loss in the lung volume, or show a spread along the 
interlobar fissures [59]. For patients with radiographic features of MPM the 
recommended second-line imaging method is venous-phase, contrast-enhanched CT of 
the thorax and the upper part of the abdomen (Figure 3).  
 
 
Figure 3. Chest CT scan showing concentric and fissural (arrows) pleural thickening in 




For a high rate of false positivity -especially after talc pleurodesis-, PET-CT is only 
recommended for assessment of patients’ eligibility for surgical resection, such as for 
evaluation of depth of chest wall invasion or for exclusion of distant metastases [58]. In 
each case, the diagnosis of MPM has to rely on pathologic evaluation, for there are no 
specific radiological or clinical features of the disease. There are several methods 
available for diagnostic sample acquisitions which differ widely in invasiveness and 
sensitivity. For patients presenting with unilateral pleural effusion, an ultrasound-guided 
pleurocentesis followed by the cytological evaluation of the pleural fluid is 
recommended [8, 61]. The sensitivity of cytology in the diagnosis of MPM varies 
substantially, ranging from 30% to 75%, mainly depending on the experience of the 
laboratories and the availability of ancillary testing [62-66].  
The observed high false-negative rate might be explained by the fact that MPM cells 
lack specific features of malignancy, malignant epithelioid cells and reactive 
mesothelial cells share many cytological features, such as low nuclear to cytolplasmic 
ratios, cell clumps with scalloped borders. Another important factor is that the 
sarcomatoid component is usually not shed into the malignant effusion, that, as a 
consequence, results paucicellular [55]. In summary, the first diagnosis of MPM is often 
based on cytology, but in most cases a tissue biopsy is needed to assess invasion and to 
confirm the primary MPM diagnosis [61, 67]. However, in patients to frail for further 
invasive interventions, a diagnosis based on cytology alone is accepted [8, 68]. 
In patients who are candidates for chemotherapy or multimodal therapy, a tissue sample 
should be obtained. This might be carried out through video-assisted thoracoscopy 
(VATS) providing an opportunity to directly visualize any suspicious lesions 
throughout the pleural surface and to gain sufficiently large and deep tissue samples 






Figure 4. (A) and (B) Visualization of the pleural surface and MPM through VATS. (C) 
Forceps obtaining a tissue biopsy. (D) VATS view of talc pleurodesis [70]. 
 
If the extent of the disease does not allow a thoracoscopic approach, an open surgical 
biopsy might be carried out. In patients who are not fit for VATS or surgical biopsy and 
do not have a cytologic diagnosis, an imaging guided percutan core needle biopsy 
should be carried out [61]. Blind biopsies have a lower sensitivity due to sampling error 
[71] and  higher complication rate including pneumothorax in 9.4% of the cases [72].  
Initial staging of MPM is based on contrast enhanced chest and upper abdominal CT 
scan and usually an FDG PET-CT scan. If any of these suggest lesions suspicious for 
mediastinal lymph node metastases, these should be confirmed through an 
endobronchial ultrasound-guided fine needle aspiration biopsy or mediastinoscopy in 
cases where a radical surgical intervention is considered [61, 73-75]. Also, if suspicious 
lesions on the contralateral pleura or in the abdominal cavity are the only 
contraindication for radical surgery, a contralateral thoracoscopy or laparoscopy needs 
to be performed [61]. 
Individual patients’ functional status is commonly described using the Karnofsky 
performance status scale (KPS). It ranges from 0% (dead) to 100% (no sign of disease) 
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and measures the patient’s ability to carry out ordinary tasks [76]. The Eastern 
Cooperative Oncology Group (ECOG) Scale of Performance Status (PS) ranging 
between grade 0 and 5 is a similar measure of disease related changes in the amount of 
daytime spent in bed and the patient’s need for care [77]. 
The prognostic score system of the European Organisation for Research and Treatment 
of Cancer (EORTC) is a composit score developed to assess the prognosis of MPM 
patients. It includes patient’s gender, ECOG PS, the tumor’s histological subtype, 
certainty of the MPM diagnosis and white blood cell count (WBC) [78]. Male gender, 
non-epithelioid histology, an uncertain/possible diagnosis of MPM, WBC over 8.3x 
109/L and an ECOG PS other than 0 are associated with poor prognosis, and are 
summarized in the final score after multiplication with a constant specified for each 
[79]. The prognosis is considered poor if the EORTC score  is below 1.27 [80]. 
The TNM staging system proposed by the IASLC is also used to predict patient 
outcomes and to help guide treatment decisions (Table 1) [81, 82].  
 
Table 1. Definitions of T, N and M categories according to the IASLC proposal for the 




Despite all efforts to achieve early detection, sometimes heroic surgical and oncological 
treatment, the prognosis of MPM remains dismal. Even in patients with disease limited 
to the pleura without lymph node or distant metastases (stage IA), the 5-year overall 
survival is only 16% (Figure 5) [82]. 
  
Figure 5. Overall survival of MPM patients based on the IASLC staging system from the 
8th edition of TNM Classification of Malignant Tumors by UICC. Reprinted with the 
permission of Elsevier from [82] 
 
The need for early detection of MPM in patients with known asbestos-exposure has 
emerged, and multiple screening methods, such as breath tests and circulating tumor 
markers were tested [84-88]. Nonetheless, screening remains not advised due to MPM’s 
low incidence even in a high-risk population, its subtle radiologic presentation and the 
lack of curative therapeutic options [8, 58, 61]. Although there are currently no 
biomarkers recommended for screening or as a single diagnostic test, biomarker testing 
is, however, used in the diagnosis of patients with suspicious cytology who are not fit 
enough for further invasive diagnostic procedures [89].  
 
1.3 Histopathologic features of MPM 
 
Mesothelioma remains a challenging histopathological diagnosis requiring expertise and 
extensive use of additional immunohistochemical markers. The French National 
Mesothelioma Surveillance Program reviewed the initial histological diagnosis in over 
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600 MPM cases with the involvement of at least three expert mesothelioma pathologists 
and supplemental immunohistochemical analysis. The study was able to confirm the 
diagnosis of MPM in only 67%. The study found false positive diagnoses in 13% of the 
initial MPM cases and an uncertain diagnosis was made in 17% of the reviewed cases 
[20]. The 2015 edition of the WHO Classification of Tumours of the Lung, Pleura, 
Thymus and Heart recognizes three main histological subtypes of diffuse malignant 
mesothelioma, namely the epithelioid (EMM), biphasic (BMM) and sarcomatoid 
(SMM) types [90] (Figure 6). 
 
 
Figure 6. The major histological types of mesothelioma are (A) epithelioid, (B) biphasic 
and (C) sarcomatoid. (HE, 100x, author’s photomicrographs). 
 
According to the recent IMIG recommendations, the distinction between these three 
subtypes is a mandatory part of the pathological reporting of all MPM cases, because 
the histological subtype is one of the most robust prognostic factor in MPM known to 
this date, and also influences crucial treatment decisions [63].  
EMM is associated with the longes overall survival (12–27 months), BMM confers 
intermediate prognosis (8–21 months OS), while SMM is associated with dismal 
prognosis (7–18 months OS) [42]. Patients with EMM and BMM are more often treated 
by radical surgery, than those with SMM. EMM shows a survival benefit associated 
with multimodal therapy, however, the data in relation to BMM is unclear, and patients 





1.3.1 Epithelioid type 
 
Epithelioid type MPMs are usually composed of bland, mostly cuboidal tumor cells 
with eosinophilic cytoplasm and inconspicuous nuclei, however marked atypia can also 
be present in a fraction of the cases. Mitoses are tipically infrequent [90].  
EMM has a wide range of morphological subtypes, and often shows various growth 
patterns within the same tumor. The most common growth patterns of EMM include the 
solid pattern that consists of sheets of monomorphic, mostly cuboidal cells without 
specific architectural arrangement. Tubulopapillary EMM is composed of a mixture of 
tumor cells arranged around fibrovascular cores and tubular structures. The microcystic 
variant is composed of structures similar to adenomatoid tumors, forming a lace-like 
architecture of cysts of variable size. Microcystic morphological variants are sometimes 
associated with a myxoid stroma. The trabecular subtype is characterized by tumor cells 
arranged in thin rows embedded in desmoplastic stroma. Micropapillary subtype tumors 
are composed of small papillary structures lacking a fibrovascular core [90]. The 
pleomorphic variant is characterized by prominent giant cells and anaplastic tumor cells, 
often with multiple nuclei, nuclear enlargement and hyperchromasia [94]. The rare 
histological variant composed of plump, elongated epithelioid cells with marked cellular 
borders and a sheet-like growth has been termed transitional pattern [95]. EMM not 
only shows a wide variability in growth patterns, but also exhibits unconventional 
cytologic features in a minority of the cases. Variant cytologic features of EMM include 
deciduoid [96], lymphohistiocytoid [97] small cell [98], rhabdoid, signet ring and clear 
cell features [99]. 
The prognostic role of histomorphology, with an emphasis on growth patterns has been 
studied extensively in a variety of solid malignancies [100-102]. The 2011 
IASLC/ATS/ERS proposal recommended the use of an architecture based classification 
for invasive lung adenocarcinoma (LADC), introducing the lepidic, acinar, papillary, 
solid and micropapillary predominant histological subtypes [103]. Growth patterns of 
lung adenocarcinomas have since been established as independent prognostic factors by 
several studies [104, 105]. A predominant lepidic growth pattern of LADC shows an 
indolent clinical behavior and excellent 5-year survival after surgical resection [106, 
107]. Predominant solid and micropapillary patterns, however, were associated with 
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significantly shorter OS [108, 109]. The presence of non-predominant solid or 
micropapillary patterns in resection specimens was associated with intermediate patient 
outcomes: significantly worse than those without such areas, however, significantly 
better than those with predominant solid or micropapillary growth [110]. Solid and 
micropapillary patterns were associated with an elevated risk for lymph node metastases 
[106], and in case of solid predominant tumors with multiplex, early, extrathoracic 
recurrences [111]. Growth pattern based classification of LADC is not only of 
prognostic relevance, but might be associated with distinct driver gene alterations [112-
114], as well as a predictor of patients benefiting from adjuvant chemotherapy after 
surgical resection [115, 116]. Patients with early stage disease and a solid or 
micropapillary predominant component are found to benefit from adjuvant 
chemotherapy, while no significant benefit from adjuvant chemotherapy was found in 
the patients subgroup with acinar or papillary patterns [117]. Similarly, on eximanation 
of small biopsies of advanced stage patients receiving adjuvant platinum based therapy 
high-grade (micropapillary and solid predominant) patterns were significantly 
associated with an increased progression-free and overall survival in comparison to 
intermediate grade tumors [118]. 
In contrast to lung cancer, limited data is available in the literature on the potential 
prognostic role of the different predominant patterns in malignant pleural mesothelioma. 
A study analyzing 114 EMM samples found 16 myxoid-microcystic variants and 
identified it  as positive prognostic factors in EMM, being associated with significantly 
longer OS than solid, micropapillary and pleomorphic subtypes [119]. Another study 
found predominant solid pattern tumors associated with worse patient outcomes in 
comparison to non-solid variants among 708 EMM samples [120]. The tumors showing 
a transitional pattern are associated with exceptionally short OS [95]. Similarly, the 
pleomorphic subtype also shows an association with dismal clinical outcomes 
comparable to that of BMM [94, 95, 119, 121, 122]. Although the 2015 WHO 
classification of MPM included the pleomorphic and transitional patterns among the 
variants of EMM, the 2019 proposal of European Network for Rare Adult Solid 
Cancers/International Association for the Study of Lung Cancer (EURACAN/IASLC) 
on histologic classification of MPM includes these two patterns not only in the EMM, 
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but also among the subtypes of SMM based on their dismal prognosis, a finding, 
however, that still needs confirmation [99]. 
Several studies investigated cellular features of mesothelioma tumor cells in correlation 
with patient outcomes. The presence of necrosis was found to be associated with worse 
prognosis in multiple studies, as well as the degree of nuclear atypia and elevated 
mitotic counts [120, 123, 124]. Additionally, more delicate nuclear and cytological 
features were also evaluated in EMM. While the presence of atypical mitoses and 
prominent nucleoli showed significant prognostic power, intranuclear inclusions and a 
low cytoplasmic/nuclear ratio did not exhibit such properties, and the impact of 
chromatin architecture and density is still ambigous [123, 124]. 
The resently established nuclear grading system predicts patient outcomes. It is based 
on a three-tier assessment of nuclear atypia, and a three-tier scoring of mitotic counts. 
These scores are combined into nuclear grades I to III [120, 123].  
A further grading system, the recently proposed mitosis-necrosis score is computed 
based on the presence of necrosis and a two-tier scoring of mitotic figures, the cut-off 
value being 5 per 10 high power fields [120]. In a recent validation study, both the 
three-tier nuclear grading and the mitosis-necrosis score was confirmed to be useful in 
predicting patient outcomes in a cohort where 87% of the tissue samples were small 
biopsies [125]. 
 
1.3.2. Differential diagnostics of EMM regarding other carcinomas in the lung  
 
The distinction between EMM and lung carcinomas involving the pleura or pleural 
metastases is often challenging and requires the use of immunohistochemistry. Due to 
the variable specificity and sensitivity of the commonly used antibodies, the IMIG 
guideline for the diagnosis of MPM recommends the use of a minimum of two positive 
markers for confirmation of mesothelial origin, and two negative markers to exclude 
carcinomas [63]. 
Lung malignancies and metastases involving the pleura are far more common than 
MPM, thus, it is important to use a panel of organ-specific immunhistochemical 
markers selected based on the patient’s clinical history and the differential diagnosis. 
The most commonly applied negative markers are listed in Table 2. 
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Table 2. List of immunohistochemical markers commonly negative in MPM and positive 
in carcinomas that frequently involve the pleura either through direct infiltration or 
through metastases [63, 90]. 
Markers negative in MPM and positive in carcinomas 
 Sensitivity Specificity vs. MPM 
Lung squamous cell carcinoma 
P40 100% 97.5% 
Claudin 4 95% 0% 
MOC31 97-100% 85-98% 
BG8 80% 93-97%  
Adenocarcinoma markers 
MOC31 95-100% 85-98% 
Ber-EP4 95-100% 74-87% 
BG8 90-100% 93-97% 
CEA (monoclonal) 80-100% > 95% 
Markers of lung origin 
TTF-1 80% High 
Napsin-A 80% High 
Markers of breast origin 
GCDFP15 30-40% High 
Mammaglobin 50-85% High 
Markers of renal origin 
PAX8 70-100% Unknown 
PAX2 80% Unknown 
Claudin 4 90% 0% 
CD15 (Leu-M1) 60% High 
 
The most commonly used mesothelial markers include WT-1, calretinin, podoplanin 
(D2-40 and CK 5/6 [90]. The sensitivity and specificity of these markers are described 




Table 3. The most common and sensitive mesothelial markers used in the 
immunohistochemical diagnosis of epithelioid MPM, and their reactivity in lung 
squamous cell carcinoma and adenocarcinoma [63]. 
Positive markers for epithelioid mesothelioma 
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75-100% 100% 2-20% (focal) 
 
Discrimination between reactive mesothelial proliferations and EMM is yet another 
diagnostic challenge. In addition to morphological characteristics, 
immunohistochemical detection of the loss of nuclear BAP1 staining is useful. The loss 
of nuclear BAP1 staining was detected by immunohistochemistry in 40-77% of 
epithelioid MPMs [126-128] and was found to be significantly associated with 
nonsynonimous genetic alterations of the BAP1 gene [129]. BAP1 negativity was 
exclusively observed in MPM but not in benign, reactive lesions of the pleura [130]. In 
a further study, the sensitivity, specificity, positive predictive value, and negative 
predictive value of the loss of nuclear BAP1 staining was estimated to be 61%, 100%, 
100%, and 32%, respectively [127]. Another study proposes that combined use of 
MTAP – a highly sensitive surrogate marker of 9p21 deletions, a common event in 
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MPM – and BAP1 immunohistochemistry improves sensitivity of the distinction 
between MPM and benign proliferations [131]. 
 
1.3.3. Biphasic type 
 
BMM contains an epithelioid component intermixed with a sarcomatoid or spindle cell 
component, both constituting at least 10% of the tumor area.  
The diagnosis of biphasic MPM often represents a diagnostic challenge. In an 
international interobserver agreement study 42 patients’ MPM samples originally 
classified as biphasic MPM were reviewed by fourteen pathologists with special interest 
in mesothelioma. The 544 expert opinions on the diagnosis for 42 cases showed 
moderate interobserver correlation (weighted κ-value=0.45). The original diagnosis of 
BMM was agreed in 71% of the cases, in 17% the case was reclassified as EMM, and in 
12% as pure SMM [95]. 
The identification of a sarcomatoid component is of outmost importance, since it is a 
negative prognostic factor and is associated with worse patient outcomes in a radical 
surgery setting [95]. Both the WHO and the EURACAN/IASLC recommend that the 
amount of spindle cell component be reported because of its possible prognostic role 
[90, 99]. Patients with BMM containing less than 20% sarcomatoid elements were 
found to have significantly longer median OS [95], while another study reported a 
similar association between the amount of sarcomatoid elements and OS using a cutoff 
or 50% [132].However, a frank sarcomatoid component of BMM is hard to be 
distinguished from reactive fibrosis accompanying an epithelioid MPM. The malignant 
spindle cell population almost invariably shows an at least focal positivity with 
pancytokeratin antibodies [133] and broad spectrum anti-keratin cocktails such as 
AE1/AE3 [90]. Reactive fibroblastic proliferations might also be positive with 
pancytokeratins, but are arranged in regular fascicles that respect mesothelial 
boundaries, in contrast to the haphazard appearance of a malignant proliferation [63]. 
Other ancillary techniques are helpful in this setting, such as the BAP-1 
immunhistochemical staining [134] and the detection of homozygous p16/CDKN2A 
deletion by fluorescent in situ hybridization (FISH). The homozygous deletion of 
p16/CDKN2A was detected in 94.7% of BMM, and the concordance between the 
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p16/CDKN2A status of the epithelioid and sarcomatous component was 100%. The 
non-neoplastic fibrous stroma showed intact p16/CDKN2A status in 100% of the cases. 
The loss of the nuclear BAP-1 staining was reported in 38.5% of the BMM cases, but 
no such loss was observed in the atypical fibrous stroma of EMM cases [135]. 
 
1.3.4 Sarcomatoid type 
 
SMM is composed fascicles of spindle cells arranged in a haphazard pattern. The 
sarcomatoid tumor cells show remarkable morphological variability, and might have 
plump or thin cytoplasm, nuclei with various degree of atypia and exhibit a wide range 
of mitotic counts [90]. Heterologous elements such as rhabdomyo-, osteo- or 
chondrosarcomatous components might be present [136]. Desmoplastic mesothelioma is 
a distinct subtype of SMM, and is characterized by dense, eosinophilic, hyalinized 
stroma, and bland, atypical spindle cells forming no remarkable structure (also known 
as patternless pattern) [90]. The pleomorphic and transitional patterns -currently 
regarded by the WHO classification as variants of EMM - might be reclassified as 
SMM subcategories in the future [94, 95].The main differential diagnoses for SMM are 
various metastatic or primary soft tissue sarcomas, which are mostly CK negative, while 
virtually all SMM show at least focal CK positivity [133]. The diagnostic role of broad 
spectrum keratins as positive markers is especially important, since mesothelial 
markers, such as WT1 and calretinin, only stain SMM cells in about 50% of the cases, 
and the D2-40 immunostaining, while highly sensitive, lacks specificity [137, 138]. 
GATA3 recently emerged as a positive marker for SMM that might play a role in 
distinguishing between SMM and the sarcomatoid carcinoma of the lung [139]. The 
homozygous deletion of p16/CDKN2A was detected through FISH in 100% of SMM 
samples by a recent study [140]. The diagnostic challenge of discriminating organizing 




1.4 Treatment modalities in MPM 
1.4.1 Systemic therapy 
 
Since the early 2000s the first line treatment of MPM patients not eligible for surgery 
has been a combination chemotherapy based on antifolate and platinum agents [141]. 
Cisplatin in combination with either raltitrexed or pemetrexed improves overall survival 
in comparison to cisplatin alone [8, 142, 143], and the combination of cisplatin and 
pemetrexed is the most commonly used frontline treatment to date [144]. Carboplatin is 
also an acceptable alternative to cisplatin in combination with antifolates, and might be 
better tolerated for patients of elder age or comorbidities [145]. In unresectable cases the 
median overall survival achievable through combination chemotherapeutic treatment 
was found to be approximately 12 months in a randomized trial [142], while on a 
population-based level median overall survival of patients treated with chemotherapy 
increased from 10.1 months observed before the introduction of combined 
chemotherapy to 13.1 months after that [146]. The combined use of bevacizumab and 
cisplatin plus pemetrexed provided significantly longer OS for patients newly diagnosed 
with MPM, and improved 20-month survival rates to 90%, and 40-month survival to 
20% in contrast to 77% and 16% achived through cisplatin-pemetrexed only [147]. 
Based on these findings the combination containing bevacizumab is now included 
among the first line treatment regimens in the National Comprehensive Cancer 
Network’s Guidline [148]. 
The single randomized trial comparing the patient outcome between active symptom 
control (ASC) alone and ASC in combination vinorelbine as first-line chemotherapy 
treatment found a 2-month survival benefit for the latter group (7.6 months vs. 9.5 
months) [149]. However, there is no established biomarker recommended for standard 
use for the prediction of patient’s response to first-line chemotherapy [141]. 
Among patients receiving first-line chemotherapy the median time to progression is 5 
months, and 25% of the patients are refractory to first-line agents, thus, a large number 
of patients receive second-line treatment [13]. In spite of all efforts in developing 
efficient options for patients after progression of disease, no validated second line 
treatment of MPM has been established so far [150]. Vinorelbine [151] and gemcitabine 
alone [152] are both commonly used in this clinical setting, and have shown efficacy in 
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retrospective studies, but due to the study designs interpretation of these data remains 
difficult. Premetexed has been found to be effective as a single agent [153], however, its 
common inclusion in first-line regimens limits its use in second-line in a variety of 
cases, although rechallenge therapy remains an option still to be evaluated [154]. 
 
1.4.2 Radiotherapy  
 
The application of RT alone is not recommended because of its poor efficacy and is 
only used either as part of palliative care in an attempt to control chest pain and other 
tumor mass related obstructive symptoms, or in multimodality treatment protocols [8, 
155]. The results of RT in terms of local control are complicated by the complex growth 
of tumors along interlobar fissures and into diaphragmal recesses. The associated 
toxicity is high due to the vicinity of vital organs including the remaining lungs after 
pleural decortication [8, 156]. 
Recent retrospective studies analysed patient outcomes after receiving either intensity 
modulated radiation therapy or 3D conformal radiation as part of multimodality therapy. 
One study found that of 2846 patients undergone surgical treatment, 213 (7%) received 
adjuvant RT. The study found a survival benefit after adjuvant RT only in stage I-II 
patients (p=0.024) in contrast to stage III (p=0.890) and IV patients (p=0.183) [157]. 
Another study analysed data of 24914 patients, 23.8% received surgical therapy only, 
and 3.1% surgery plus at least 40 Gy radiaton therapy. The two subgroups had 16.59 
months and 21.4 months OS, respectively (p<0.001). In multivariable analysis, 
receiving chemotherapy, surgery plus radiotherapy and a higher socioeconomic status 
were found to be independent predictor of improved survival [158]. Analysis of 
retrospective data of The National Cancer Data Base in the United States identified 
IMRT as the most commonly used technique for adjuvant RT, and did not find a 
significant difference among patients receiving 3D CRT or IMRT [159]. 
 
1.4.3 Surgical therapy  
 
Only few cases are eligible for radical intent surgery, mostly young patients with 
localized disease, good performance status and epithelioid histology [150, 160]. The 
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aim of radical procedures is to remove all visible tumor tissue, however, due to the 
highly complicated location of these tumors it is virtually impossible to achieve 
microscopically confirmed complete tumor-free resection margins [8]. The surgical 
procedures currently applied with the intent of achiving macroscopic complete resection 
include extrapleural pulmonectomy (EPP, also known as pleuropneumectomy), which 
involves the en bloc resection of both the parietal and visceral pleura, as well as the 
ipsilateral lung, or lung sparing options pleurectomy/decortication (PD) or extended 
pleurectomy/decortication (ePD), also meaning the removal of both pleural plates, but -
if required- with the removal of the diaphragm and/or pericardium [161]. 
In patients who underwent extrapulmonal pneumonectomy a median overall survival of 
12 months was observed, while those having received pleurectomy/decortication 
treatment had 16 months median overall survival, with operative mortality rates of 7% 
and 4%, respectively [162]. Outcomes after EPP have been assessed in the MARS 
feasibility study, in which 50 patients all eligible for surgical resection were randomly 
assigned to either EPP plus hemithoracic irradiation of the affected side or to no EPP, 
both arms in combination with three cycles of platinum-based neoadjuvant 
chemotherapy and further adjuvant chemothrapy. In the no-EPP arm of the study an OS 
of 19.5 months (13.4-time not reached at the time of publication), while for patients 
receiving EPP as part of trimodality treatment OS was 14.4 months (5.3–18.7) [163]. 
Further systematic review of data on the efficacy and safety of EPP reported, that 
patients receiving EPP as part of trimodality treatment also involving adjuvant 
chemoradiotherapy had a median OS of 13-23.9 months, as well as perioperative 
mortality ranging between 0-11.8%, perioperative morbidity of 22-82% and major 
morbidity rates between 12.5 and 48% [164]. 
Due to a possibly more favorable patient outcomes, lower perioperative mortality rate 
and its feasibility for patients over 65 years [165, 166], as well as its superiority in QoL 
analyses [167] pleurectomy/decortication is becoming the preferred surgical 
intervention for MPM patients. 
DOI:10.14753/SE.2020.2421
 32 
1.4.4 Multimodality treatment  
 
Most guidelines on MPM management recommend the application of radical surgery 
only in a selected set of patients, in specialized centers, and favorably in combination 
with chemo- and/or radiotherapy [168]. 
In a study mainly including patients with epithelioid histology tumors (87.3%), a 
median OS of 35.6 months (15.4–42.6) and good locoregional disease control was 
observed among patients who were able to complete MMT. However, due to serious 
complications only 45% of the patients concluded induction chemotherapy, surgery and 
postoperative irradiation. Postoperative mortality was 11.1%, and 44.4% experienced 
major complications including rethoracotomy for haemothorax, acute respiratory 
distress syndrome, pulmonary embolism, cardiac or gastric herniation and 
bronchopleural fistula among others [169]. Further studies also suggest that surgery 
alone provides dissatisfactory results, and it be used in combination with other treatment 
modalities. However, questions regarding the preferred type of induction chemotherapy 
and radiation therapy are yet to be settled [170, 171]. 
 
1.4.5 Emerging therapeutic approaches  
 
Given the dismal prognosis of MPM even in cases suitable for radical multimodal 
treatments, there are several novel therapeutic approaches currently tested in clinical 
trials, including antiangiogenic agents bevacizumab and nintedanib [147, 172], anti-
mesothelin targeted therapy[173-175], anti-WT1 vaccination [176], arginin deprivation 
[177], dendritic cell vaccination [178], anti-CTLA4 antibodies [179], anti-PD(L)1 
inhibitors [180, 181], FAK inhibitors [182], intrapleural viral therapy [183] (Figure 7). 





Figure 7. Summary of novel therapeutic approaches for MPM management. Reprinted 
with the permission of Elsevier from [184]. 
 
Bevacizumab is used in combination with cistplatin and pemetrexed as first-line 
treatment, thus, the potential role of other angiogenesis inhibitors was also investigated. 
In the phase 3 trial the addition of nintedanib to cisplatin and pemetrexed was compared 
to placebo plus cisplatin and pemetrexed in MPM patients not receiving surgical 
resection. The trial failed to confirm any of the positive effects of nintedanib on 
outcomes previously observed in a phase 2 trial [172]. 
There are various genetic alterations in MPM that might be tested in biopsy samples and 
predict which molecularly targeted therapeutic approach is most likely to be beneficial 





Figure 8. There are several genetic alterations wich are proposed to have a predictive 
implication in targeted therapy of MPM. Reprinted with the permission of Springer 
Nature from [42]. 
 
Tumors harboring NF2 mutations might be targeted by FAK inhibitors, such as 
defactinib. However, a phase 2 clinical trial failed to prove any statistical difference in 
PFS, OS or quality of life between patients who after first line chemotherapy received 
defactinib maintenance treatment versus those who received placebo, and the result was 
found to be independent of NF2 mutation status [182]. 
Another potential target is the subgroup of ASS1 (argininosuccinate synthetase 1) 
deficient MPMs. The use of arginin-lowering agent ADI-PEGO20 in a phase 2 trial 
involving 68 patients, has provided a statistically significant improvement in median 
PFS (3.2 months versus 2.0 months) [177]. 
The anti-CTLA4 antibody tremalimumab failed to increase OS in patients pretreated 
with first and second line chemotherapy [179]. PD1 inhibition is studied in several 
clinical trials, of which the most promising so far has achieved 12-week disease control 
in 44% and 52% of the patients using either nivolumab or nivolumab plus ipilimumab, 
respectively [180]. The combination of durvalumamb and platinum plus pemetrexed 
chemotherapy has resulted of sufficient activity, a median PFS of 6.9 months and 
objective tumor response in approximately 50% of the cases [181]. 
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To overcome the relatively immunosuppressing microenviroment typical of MPM, 
various immune-activating therapies have emerged and are currently tested in pilot 
studies involving a limited number of patients. Chimeric antigen receptor (CAR) T-cells 
extracted from the patients and then genetically engineered to be activated by MPM 
specific cell surface protein mesothelin and readministered the modified T-cells into the 
patients represent another novel direction that is currently being investigated in various 
solid malignancies [173]. Another approach is the presentation of allogenic tumor lysate 
to monocytes extracted from the patient and the re-injection of allogenic activated 
dendritic cells into the patient [178]. 
 
1.5 The molecular landscape of MPM 
 
Molecular alterations in MPM include mutations and copy number alterations, as well 
as epigenetic changes. Strikingly, the most frequently involved genes are tumor 
suppressors and regulators of gene expression (Figure 9).  
 
Figure 9. Frequency (%) of genetic alterations detected in MPM based on DNA-
sequencing and copy number analysis of 87 samples from TCGA-MESO cohort [185]. 




Despite the growing number of high throughput genomic analyses and the increasing 
data on the molecular characteristics of MPM, no frequent oncogenic driver has been 
discovered to this date [188-190]. 
 
1.5.1 Cell cycle regulation pathways 
 
The CDKN2A locus encodes the p16INK4a and p14ARF tumor suppressor proteins that are 
inhibitors of the cell cycle as depicted in Figure 10. The protein p16INK4a binds to cyclin 
dependent kinases (CDK4/6) and inhibits their kinase activity. Uninhibited CDK4/6 
binds cyclin D1 and their complex phosphorylates the retinoblastoma protein (pRb) 
which releases the transcription factor E2F1. The latter protein promotes the 
transcripition of genes involved in the transition from G1 to S phase. The alternate 
reading frame product of CDKN2A, p14ARF inhibits MDM2, thus, activates p53 and 
prevents its MDM2-mediated degradation [191, 192]. The activation of transcription 
factor p53 results in the transcription of numerous genes involved in cell cycle arrest, 
senescence, apoptosis and differentiation [193]. 
 
Figure 10: The products of the CDKN2A gene p14ARF and p16 INK4a play a role in the 




The loss of CDKN2A locus through homozygous deletion of 9p21 occurs in 67-83% of 
all MPM cases, while its frequency is up to 100% in SMM [140, 186, 191, 194, 195]. 
Less frequent causes for p16 inactivation are hypermethylation and point mutations of 
the gene CDKN2A [196, 197]. Several studies reported a strong association between the 
loss of CDKN2A and significantly shorter OS in MPM patients [197-199]. 
Recurrent mutations in the gene TP53 are relatively infrequent in MPM [186, 194], 
however, its reported frequency varies widely and was found to be 57% in one 
retrospective study [129], while only 16% by another recent study [200]. The germline 
mutation of the TP53 gene is associated with the Li-Fraumeni cancer syndrome. The 
patients carrying this type of TP53 mutations frequently develop breast cancer, 
carcinomas of the adrenal cortex or sarcomas, however, are only occasionally diagnosed 
with MPM [28]. 
 
1.5.2 BAP1 and DNA damage repair 
 
BRCA1-Associated Protein 1 (BAP1) is a deubiqitinating enzyme consisting of three 
main domains, namely the N-terminal ubiquitin carboxyl hydrolase domain, a middle 
portion containing binding sites for complex forming and a C-terminal domain also 
important in interactions with other proteins [44]. When located in the nucleus BAP1 
acts as a tumor suppressor through regulation of the cell cycle and differentiation [201] 
and plays an essential role in the repair of double strand DNA break repair through an 
interaction with a variety of recombination proteins, such as Breast cancer type 1 
susceptibility protein (BRCA1) and BRCA1-associated RING domain protein (BARD1) 
[202] as shown in Figure 11. When located in the endoplasmic reticulum (ER) BAP1 
modulates intracellular calcium levels and promotes apoptosis [203]. Cells with an 
impaired BAP1 function show reduced mitochondrial Ca2+ levels, and as a consequence 
are more likely to show a metabolic shift towards aerobic glycolysis [204], and are not 




Figure 11. BAP1 has different functions in a nuclear localisation and in the 
endoplasmic reticulum. The author’s drawing based on [28]. 
 
The gene encoding BRCA1-Associated Protein 1 (BAP1) is located on chromosome 3’s 
short arm (3p21.1) and is one of the most frequently affected by genetic alterations in 
MPM. The frequency of alterations leading to the loss of BAP1 function is within a 
wide range between different studies, it is reported to occur in 23-63% of MPM cases 
[194, 200, 205-207]. The mechanisms of the inactivation of BAP1 include loss-of-
function mutations, copy number loss of chromosome 3p21 and gene fusions [206]. 
Hotspot regions of the BAP1 gene with genetic alterations are exon 13 and 17, where a 
study identified variations in 38% and 25% of the patients, respectively [129]. The loss 
of nuclear localization of the BAP1 protein detected by immunohistochemistry 
correlates with the nonsynonimous variations of the BAP1 gene identified by next 




1.5.3 Hippo pathway 
 
The Hippo pathway is a highly conserved signaling pathway that plays a regulatory role 
in organ growth, tissue regeneration and preventing tumorigenesis through restraining 
the cell cycle, controlling cellular differentiation and promoting apoptosis. 
 
 
Figure 12. Main actors of the Hippo pathway. The author’s drawing based on [208] 
 
The kinase cascade of the Hippo pathway (Figure 12) include the MST1/2-SAV1 
complex that activates the LATS1/2-MOB1A/B complex through phosphorylation, 
which then phosphorylates the YAP/TAZ complex. When phosphorylated, the nuclear 
effector YAP/TAZ transcriptional coactivators are excluded from the nucleus and thus 
inactivated. When the activity of the Hippo pathway is low, YAP/TAZ is able to enter 
the nucleus, where it interacts with transcription-enhancer activator domain 
transcripition factor (TEAD) and activates the transcription of several target genes 
involved in cell proliferation and the evasion of apoptosis. Upstream regulators of the 
pathway are reported to mediate extra- and intracellular signals, such as polarity, 
cellular interactions through adherens junctions, mechanical and other stress signals. 
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Among these regulators, NF2/Merlin and KIBRA are cooperating proteins located at the 
apical membrane of cells that interact with LATS1/2 and through the activation of the 
Hippo pathway mediate contact inhibition in cell cultures [208]. 
In MPM the loss of function alterations of genes NF2 and LATS1/2 occur relatively 
frequently, while alterations of MST1 and SAV1 are also reported [206]. The 
inactivation of the negative regulators of YAP/TAZ complex leads to the constitutive 
activation of the complex [209]. Although oncogenic alterations of the YAP1 and 
WWTR1 gene (encoding TAZ) are relatively frequent in triple-negative breast cancers, 
non-small cell lung cancer, it is a rare occurrence in MPM [210, 211]. 
The frequency of genetic abnormalities affecting the NF2 gene is reported to be 14-
50%, mostly being missense, nonsense or splice site mutations, and less commonly 
losses of chromosome region 22q12 encoding NF2 [186, 194, 200, 205, 206, 212]. 
Alterations of the NF2 locus is reported to occure significantly more often in patients 
not exposed to asbestos [190]. 
Neurofibromatosis type 2 is associated with germ-line mutations in the NF2 gene, but 
this autosomal dominant disease is not associated with increased risk to develop MPM, 
even though there is an overlap between somatic mutations detected in MPM and those 
in hereditary neurofibromatosis [213]. 
The loss of function alterations of tumor suppressor LATS2 occur through the 
homozygous deletion of 13q12 encoding the LATS2 gene, which was reported to occur 
in 10 out of 45 MPM samples [214], or through somatic mutations of the LATS2 gene 
[206, 215]. The loss of LATS1 function occurs most frequently through a chromosomal 
translocation which leads to the fusion of the LATS1 and PSEN1 (presenilin-1) genes, 
and the fusion protein product lacks the kinase activity which is essential in the 
inhibition of YAP [215]. 
Other altered pathways include the mTOR, histone methylation and RNA helicases 




1.6 Telomere and telomerase 
1.6.1 Structure and function  
 
The telomere region of eukaryotic chromosomes is located at the extremes of the 
chromosomes and is “capped” by a large nucleoprotein complex that prevents 
breakdowns and fusions between chromosome ends during mitosis [216]. Its DNA 
component contains several kb of the repetitive sentence d(TTAGGG) in humans [217]. 
Telomeric DNA is characterized by the protruding extreme of the G-rich strand, which 
is approximately 200 nucleotides long and is a consequence of the mechanism of  
terminal replication [218]. The overhang produced at the end of the lagging strand 
might form G-quadruplexes [219] or a T-loop which is a circle of curled-up single 
strand DNA forming a triple-strand structure at the very end, called displacement loop 
[220] (Figure 13A). 
 
Figure 13. Telomeric region of human chromosomes. (A) G overhang forms a 
protective T-loop and through invading the dsDNA to form a D-loop. (B) Shelterin 
complex of telomere binding proteins protecting the chromosomes’ ends from triggering 
a DNA damage response. The telomerase complex consisting of the protein TERT and 
template RNA TERC components recognizes the 3’-end of the single strand G overhang 
and elongates it. Reprinted with the permission of Springer Nature from [221]. 
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The telomeric region is bound by the shelterin complex in human cells that consists of 
six proteins, namely TRF1 and TRF2, RAP1, TIN2, TPP1 and POT1. TRF1 and TRF2 
both need to build dimers to be able to bind to 5’-YTAGGGTTR-3’ sequences of 
double strand telomeric DNA. POT1 interacts with single strand G overhang at 5’-
TAGGGTTAG-3’ sequences and interacts with the TRF1 and TRF2 homodimers 
through proteins RAP1, TIN2 and TPP1 (Figure 13B). 
During cell division the length of the telomere decreases at each passage of the 
replication fork due to the inability of conventional DNA polymerases to fully duplicate 
the 3’ end of linear DNA molecules [222]. Telomerase plays an essential role in 
maintaining chromosomal integrity by preventing the loss of genetic material caused by 
incomplete terminal replication and compensating for the shortening of the telomere 
region through de novo addition of TTAGGG repeats. The telomerase enzyme complex 
is a reverse transcriptase containing the catalytic subunit TERT encoded by the gene 
hTERT in humans and the RNA template component TERC [221] (Figure 13B). 
Telomerase is physiologically expressed in a strictly regulated manner in germ cells and 
stem cells, but its activity is restrained in somatic cells [216]. Telomere repression is a 
mechanism for the prevention of uncontrolled cellular proliferation. In cells lacking 
telomerase expression the erosion of the telomere leads to the activation of DNA 
damage response pathway and cells enter senescence [223]. TERT also plays telomere-
independent roles both in cooperation with the TERC RNA template and independently 
of that. Such functions of TERT include the regulation of targets of the Wnt-pathway, 
the genesis of double strand precursors of silencing RNAs, and the maintenance of 
mitochondrial fitness [224]. 
 
1.6.2 Telomere lengthening and telomerase in disease  
 
Telomere shortening can lead to impaired tissue regeneration and accelerated aging. On 
the other hand, constitutive expression of the telomerase permits uninhibited cell 
division and immortalization but is also associated with increased chromosomal 
instability [225]. 
The constitutive expression of the TERT gene and telomerase activity is detected in 85-
90% of all malignant tumors [223, 226], and is considered a hallmark of cancer 
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[227].There are several mechanisms underlying the telomerase reactivation and 
telomere lengthening in malignant cells. 
Abnormal expression of positive regulators of the TERT gene such as the oncogene 
MYC induce TERT expression and leads to an increased telomerase activity [228, 229]. 
Epigenetic factors might also lead to an increase in TERT activity. The TERT promoter 
is generally not methylated in normal cells, however, hypermethylation of the promoter 
at the TERT hypermethylation oncological region (THOR) occurs in malignant cells 
and accounts for upregulation of TERT expression [230]. SMYD3 regulated histone 
H3-K4 trimethylation are factors leading to constitutive activation of the telomerase 
[231], as well as the recruitment of histone acetyltransferases or histone deacetylases 
that might cause telomere reactivation depending on the cellular context [232]. Viruses 
such as Epstein-Barr virus, cytomegalovirus, human papilloma virus, hepatitis B and C 
encode exogenous positive regulators of hTERT [233]. 
Telomerase-independent, recombination-based mechanisms of telomere maintenance, 
the so called alternative lengthening of telomeres (ALT) are reported in several human 
malignancies, and are associated with the loss of ATP-dependent helicase encoded by 
ATRX or the H3.3-specific histone chaperone DAXX both of which would otherwise 
repress ALT [234]. The loss of ATRX and DAXX function occurs most commonly in 
pancreatic neuroendocrine tumors [235] sarcomas [236, 237] and childhood 
glioblastomas [238]. 
According to recent data, rearrangements and focal amplifications of the TERT gene are 
relatively rare. Amplifications occur in approximately 4% of malignancies, but it is 
more common in lung adenocarcinomas and squamous cell carcinomas, as well as in 
ovarian cancer, adrenocortical and esophagus carcinomas [239]. Rearrangements have 
been identified in high-risk neuroblastomas, however do not seem to play a crucial role 




1.7 TERT promoter mutations  
 
1.7.1 Patomechanism of TERT promoter mutations 
 
The TERT gene located on the short arm of chromosome 5 harbors a single proximal 
core promoter located at -330 to +37 upstream and downstream relative to ATG. The 
promoter region lacks conventional regulatory elements like CAAT and TATA boxes, 
however, has multiple binding sites for transcriptional factors, namely p53, c-myc, p21, 
SP1, ETS, E2F, HIF1 and AP1 [242]. There are three hotspots within the TERT 
promoter where mutations most commonly occur: at -124 (-124 C>T), -146 (-146 C>T), 
or -57 (-57 A>C), the mutations also frequently designated C228T, C250T and 23 
A161C in the literature (Figure 14). Further recurrent TERT promoter mutations were 
identified in melanoma, namely tandem CC>TT mutations at -124/-125 or -138/-139 
from ATG, which is likely of UV-related origin [243, 244]. All three of these point 
mutations create de novo ETS binding sites. Proteins GABPA and GABPB belonging to 
the ETS family form heterotetramers and are able to bind to the de novo ETS motif and 
activate the transcription of the TERT gene, thus, these non-coding mutations of the 
TERT promoter exert an oncogenic effect [223].  
 
 
Figure 14: Hotspot mutations of the TERT promoter create de novo binding sites for 
members of the ETS transcription family, while T > C polymorphism rs2853669 at -245 





In reporter assays, TERT promoter mutations were associated with a two to four fold 
increase in promoter activity [244, 246, 247] and with a higher TERT expression in a 
variety of tumors [248-251] These findings indicate that these alterations in the TERT 
promoter are most likely to be drivers rather than passanger events in tumorigenesis 
[243]. 
 
1.7.2 Germline mutations 
 
Germline mutations of hTERT may appear as autosomal dominant progeria (also known 
as dyskeratosis congenita) [252] or manifest in familial idiopathic pulmonary fibrosis 
[253]. In contrast with exon mutations, recently discovered high penetrance germline 
mutations of the TERT promoter region in positions -124 and -146 were found in a 
melanoma-prone family where patients presented with extensive melanoma history in 
their family and early-onset, advanced stage disease [244]. Interestingly, however, 
germline mutations have not been associated with any other tumor type. 
 
1.7.3 Somatic mutations 
 
The first studies investigating the clinicopathological relevance of TERT promoter 
mutations reported on its high frequency in malignant cuateneous melanomas [244, 
246] The frequency of TERT promoter mutations have since been found to vary widely 
among malignant tumors (Figure 15). In addition to malignant melanoma the highest 
mutation rates are observed in basal cell carcinoma [254], glioblastoma, and urothelial 
bladder cancer, while hepatocellular carcinoma, thyroid cancer, head and neck 
squamous cell cancer [223]. The mutation rates are higher in poorly and 
undifferentiated thyroid carcinomas (42.9%, combined) in comparison to well 
differentiated papillary and follicular carcinomas of the thyroid (12.1% and 14.0%, 
respectively) [255]. Strikingly, in several common malignancies, such as breast, lung 




Figure 15. The frequency of TERT promoter mutations, TERT amplifications and other 
structural alterations  in several solid malignancies based on the TCGA dataset [239] 
and data recently published on MPM [249]. 
 
In several malignancies TERT promoter mutations have been shown to be associated 
with unfavorable patient outcomes, eg., diffuse gliomas [256], primary glioblastomas 
[257], bladder cancer [258] and cutaneous melanoma [259]. Importantly, TERT 
promoter mutations are prognostic factors that help identify patients at higher risk for 
disease recurrence and disease specific death in potentially indolent tumors, such as 
papillary thyroid carcinoma [260], follicular thyroid carcinoma [261, 262] and 
meningioma [263].  
 
1.7.4 Common single nucleotid polymorphism rs2853669 
 
The common polymorphism rs2853669 C>T has been shown to modify the effect of 
oncogenic TERT promoter mutations through disruption of a preexisting putative Ets2 
binding site in the promoter region. In cell lines carrying both the variant allele of the 
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SNP and the -124C>T activating TERT promoter mutation the promoter activity 
significantly decreased in comparison to cells carrying a mutation and the wild-type 
allele of the SNP, while only a moderate difference in activity was observed in cells 
harboring the -146C>T mutation. Regarding patient outcomes the presence of the 
variant allele dissolved the negative prognostic effect associated with TERT promoter 
mutations in bladder cancer, while noncarriers of the variant allele harboring a TERT 
promoter mutation showed a significantly worse overall survival and an increased risk 
for disease recurrence [258]. In glioblastoma patients TERT mutation only exerts a 
negative effect on OS in patients who do not harbor a homozygous variant allele (CC) 
of rs2853669 [264, 265]. Among TERT promoter mutant glioblastoma cases a 
significant difference in survival was observed between carriers of a homozygous 
variant allele (CC), heterozygous variant allele (CT) and those with the wild-type SNP 
(TT), the latter two being associated with hazard ratios of 4.7 and 10.7, respectively 
[266]. 
 
1.7.5 TERT in MPM 
 
The reactivation of telomere function is reported to be present in virtually all MPM 
cases, while ALT activity is not detected in this tumor type [267]. The amplification of 
the 5p.15.3 chromosome region encoding TERT has been indentified in 1% of MPM 
samples according to TCGA database, while other studies report its frequency to be 
between 22 and 55%, however its association with the upregulation of TERT expression 
is not clear [249, 268]. There is limited data on the role of TERT promoter mutations in 
MPM. The sole study published so far reports the frequency of TERT promoter 
mutations to be 15.2% with 12 mutants identified among 61 MPM cell cultures (19.7%) 
and 8 promoter mutatns among 71 fresh frozen MPM tumor samples (11.3%). All the 
detected mutations occurred at the C228T hotspot. The TERT mRNA levels were 
significantly higher in cell cultures and tumor samples carrying the promoter mutation. 
Mechanisms of derepression of TERT in non promoter mutant cases remain unclear, 
however are suggested to include the expression of positive transcriptional regulator c-






We carried out comprehensive analyses of the histopathologic and molecular features of 
malignant pleural mesothelioma and evaluated their impact on patient outcomes. We 
have focused on the following objectives: 
1. In a study involving five large Central European centers for the diagnosis and 
treatment of thoracic malignancies, we investigated the prognostic impact of 
nuclear grading, the newly proposed mitosis-necrosis score and the predominant 
growth patterns of epithelioid malignant pleural mesothelioma. We also 
evaluated the associations between these variables.  
2. We aimed to find potential histomorphologic parameters that might be useful in 
recognizing patients who might benefit from a more aggressive, multimodal 
treatment, and those who do not benefit from such relatively high-risk therapies. 
3. In a further multi-center study partially overlapping with the previous study, we 
evaluated the frequency of TERT promoter mutations in malignant pleural 
mesothelioma, its correlation with other clinicopathologic features and its power 
as a prognostic factor.  
4. We also investigated the potential interaction between the common 
polymorphism rs2853669 and TERT promoter mutation in MPM. 
5. We have carried out in vitro experiments to study the mechanisms underlying 
the aggressive clinical behavior of TERT promoter mutant MPMs, and 
determined cell line forming ability, TERT mRNA expression and in vitro 
cisplatin sensitivity in cell lines with wild-type or mutant TERT core promoter 
region. 
6. We evaluated the association between the TERT promoter mutant genotype and 





3.1. Patient cohorts 
3.1.1 Study cohort in histologic subtype analysis 
 
Our multicenter study cohort consisted of 192 patients diagnosed with epithelioid 
MPM. The patients were diagnosed and treated in five large Central European centers: 
67 patinents at the University Clinic of Respiratory and Allergic Diseases between 2007 
and 2012, Golnik, Slovenia, 54 patients at the  Medical University of Vienna, Vienna, 
Austria between 1994 and 2015, 32 patients at the University Medicine Essen - 
Ruhrlandklinik, Essen, Germany between 2016 and 2018, 30 patients between 2000 and 
2007 at the National Korányi Institute of TB and Pulmonology, Budapest, Hungary, 9 
patients at the University of Zagreb, School of Medicine, Jordanovac, Croatia between 
2013 and 2014 (Table 4). 
 
Table 4. Number of patients included from five Central European centrums, intervals of 




Time period of 
diagnoses 
Median follow-up 
Golnik, Slovenia 67 2007-2012 498 days 
Vienna, Austria 54 1994-2015 426 days 
Essen, Germany 32 2016-2018 340 days 
Budapest, Hungary 30 2000-2007 326 days 
Zagreb, Croatia 9 2013-2014 387 days 
 
All 192 cases were originally diagnosed epithelioid type MPM. The diagnoses were 
made by pathologists experienced in thoracic malignancies, adhering to international 
histological and immunohistochemical criteria requiring a minimum of two positive 
mesothelial markers (calretinin, WT-1, D2-40, CK 5/6) and at least two negative 
markers for carcinoma (such as Ber-EP4, TTF-1, CEA). 
Clinical data were collected in accordance with the latest Declaration of Helsinki as 
well as with each institute’s ethical guidelines, and included patients’ age, gender, date 
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of diagnosis, and date of death or last contact. The retrospective analysis of MPM 
patients was approved by the local ethic committees in each participating center: at the 
Medical University of Vienna (#904/2009), the University Hospital Center Zagreb 
(#02/21AG) and at the University Medicine Essen (17-7773-BO). The Institutional 
Review Boards granted a waiver for the retrospective analyses at the University Clinic 
Golnik and at the National Koranyi Institute of Pulmonology. 
The 192 tissue samples included in the analysis were obtained through video-assisted 
thoracoscopy (n=106), pleurectomy (n=28) or percutaneous pleural needle core biopsy 
(n=28). In 30 cases the diagnostic procedure was not specified. All samples were 
formalin fixed, paraffin embedded and HE stained. 
As a validation cohort, we also analyzed 55 virtual slides of epithelioid MPMs openly 
available at the Cancer Digital Slide Archive which are digitalized diagnostic sections 
of specimens collected by The Cancer Genome Atlas [269]. Among these 55 sections 
there were 6 frozen sections and 49 FFPE specimens, and all of them were HE stained. 
Corresponding survival data and additional clinical variables collected by TCGA 
Research Network [270] were downloaded from the cBioPortal [187]. 
 
3.1.2 Study cohort in the TERT promoter mutation analyses 
 
For the evaluation of the TERT promoter mutations’ impact in MPM we analyzed 
samples of 182 MPM patients. The cohort included 83 patients diagnosed between 1994 
and 2016 at the Medical University of Vienna, 76 patients diagnosed between 2007 and 
2012 at the University Clinic Golnik and 23 patients diagnosed between 2013 and 2014 
at the University of Zagreb. 
This patient collective was partially overlapping with the cohort analysed in the 
histologic subtype classification study, however, included 53 non-epithelioid tumor 
samples and 14 epithelioid tumor samples from Zagreb, Croatia that were excluded 
from our morphologic classification cohort because these were already included in a 
cohort published on the topic [121]. 
Clinical data were collected according to the Declaration of Helsinki and to each 
intitute’s ethical guidelines as described in section 3.1.1. Clinical data included patients’ 
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age, gender, histological diagnosis, date of diagnosis, date of last contact or date of 
death, Karnofsky performance score, IMIG stage, EORTC prognostic score. 
 
3.2 Histological subtype analysis 
 
Samples were reviewed and classified based on their predominant growth patterns. The 
patterns were defined based on the 4th edition of the WHO Classification of Tumours of 
the Lung, Pleura, Thymus and Heart [90], and detailed in chapter 1.1.2.1 of the present 




Figure 16. Main histomorphologic variants of epithelioid MPM. (A) Tubulopapillary 
pattern (HE, 200x). (B) Solid pattern (HE, 200x). (C) Trabecular pattern (HE, 200x). 




3.3 Histological grading  
 
Nuclear atypia was assessed at 400x magnification and in the region of tumor exhibiting 
the highest degree of atypia adhering to the guidelines established by a recent study. 
Briefly, atypia was classified as mild if the tumor cell nuclei were small, uniform, 
lacked prominent nucleoli. If tumor cells contained nuclei of intermediate size and 
variable size and prominent nucleoli, atypia was considered moderate. Atypia was 
severe if more than 5% of the tumor cells contained macronucleoli, were 
multinucleated, and if nuclei were bizarre and enlarged (Figure 17) [120]. Nuclear 
atypia scores of 1, 2 and 3 were given to mild, moderate and sever atypia.  
 
 
Figure 17. Different grades of nuclear atypia. (A) Mild nuclear atypia (HE, 400x). (B) 
Moderate nuclear atypia (HE, 400x). (C) Severe nuclear atypia (HE, 400x) [271]. 
 
Mitoses were counted at 400x magnification in hot spots and given as an average of 
mitotic figures per 10 high power fields (Figure 18 A and B). Mitotic counts between 0-
1/HPF were considered low, intermediate if 2-4/10HPF and high if 5 or more/10 HPF. 
Tumors exhibiting low, intermediate and high mitotic activity were given scores of 1, 2 





Figure 18. A) Bipolar mitoses. (arrowheads, HE, 400x) B) Typical (arrowhead) and 
atypical (arrow) mitoses (HE, 400x). C) Coagulative necrosis (HE, 200x) [271]. 
 
The composit nuclear grade was computed by the addition of nuclear atypia and mitotic 
scores. Nuclear grade I was assigned if combined scores were 2-3, nuclear grade II for 
scores 4-5 and to the maximum score of 6 nuclear grade III was assigned [120, 123].  
The presence or absence of necrotic areas was evaluated at 400x magnification and used 
to compute a mitosis-necrosis score (Figure 18 C). Tumor samples with mitotic counts 
≥5 were given a score of 1, those with <5 were given 0. If necrosis is present, a score of 
1 was given, if absent, a score of 0. By addition of scores for mitoses and necrosis the 
mitosis-necrosis score was computed which thus ranges between 0 and 2 [120]. 
 
3.4 BAP1 staining 
We performed BAP1 immunohistochemistry on 75 FFPE MPM samples as described 
previously [272]. Briefly, 4 µm tissue sections were deparaffinized and rehydrated, then 
heated for 10 minutes in 10 mM citrate buffer (pH 6.0). The sections were incubated at 
room temperature for 1 hour with the primary antibody (BAP-1, Clone C-4, sc-28383, 
Santa Cruz; dilution 1:200). Antibody binding was detected using the UltraVision LP 
detection system (Lab Vision Corporation, Fremont, California). The BAP1 staining 
was evaluated in the tumor cells as described previously in the literature [134]. A 
sample was considered negative for BAP1 expression in the absence of nuclear 
reactivity, regardless of the presence or absence of cytoplasmic staining (Figure 19). 
Nuclear BAP1 positivity detected in lymphocytes, vascular endothelium and/or stromal 




Figure 19: Nuclear expression of BAP1 is considered wild-type/ positive BAP1 reaction 
(A), while the absence of nuclear staining with cytoplasmic positivity (B) or without 
cytoplasmic reaction (C) is considered aberrant expression/ negative BAP1 reaction 
(HE, 400X). Reprinted with the permission of American Association for Cancer 
Research (AACR)  from: [273]. 
 
3.5 Mesothelioma cell lines 
 
We used 22 primary cell lines established at the Medical University of Vienna between 
2009 and 2016 [274]. Additional 5 international cell lines were kindly provided by 
collaborators: the SPC111, SPC212 by Professor R. Stahel (University of Zurich, 
Zurich, Switzerland), M38K by Professor V.L. Kinnula (University of Helsinki, 
Helsinki, Finland), P31wt and its cisplatin resistant derivative, P31res by Professor K. 
Grankvist (University of Umea, Umea, Sweden). Cells were cultured in DMEM 
medium (Lonza, Switzerland) at 37⁰C in a humified incubator with 5% CO2 atmosphere 
[275]. Table 5 contains details of patients and MPM tumor histology of which the cell 




Table 5. Characteristics of MPM cell lines. With permission of AACR from: [273] 
Cell model Gender Histology TERT promoter status 
VMC-6 female epithelioid wild-type 
VMC-12 male epithelioid wild-type 
VMC-14 male epithelioid wild-type 
VMC-20 male epithelioid -124 C>T 
VMC-23 male epithelioid wild-type 
VMC-28 male epithelioid wild-type 
VMC-40 male biphasic wild-type 
VMC-45 male epithelioid wild-type 
VMC-46 male biphasic -124 C>T 
VMC-48 female biphasic wild-type 
Meso49 male biphasic wild-type 
Meso62 male sarcomatoid -124 C>T 
Meso71 male epithelioid -57 A>C 
Meso80 male sarcomatoid -124 C>T 
Meso84 female sarcomatoid -124 C>T 
Meso92 male biphasic -124 C>T 
Meso103 male epithelioid wild-type 
Meso110 male epithelioid wild-type 
VMC-58 male biphasic -124 C>T 
Meso189 male epithelioid wild-type 
Meso194 male epithelioid -57 A>C 
Meso200 male not available wild-type 
M38K NA biphasic wild-type 
SPC111 NA biphasic wild-type 
SPC212 NA biphasic wild-type 
P31 wt NA epithelioid wild-type 
P31cis NA epithelioid wild-type 
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3.6 DNA extraction and TERT promoter status analysis 
Genomic DNA from FFPE MPM samples was isolated using High Pure FFPET DNA 
Isolation Kit (Roche Diagnostics) according to the manufacturer’s protocol. Briefly, 5 
μm thick sections were cut and deparaffinized using Xylol. Tissue lysis and digestion 
was carried out overnight in a lysis buffer containing 16% Proteinase K at 56⁰C shaking 
at 600 rpm in a Thermomixer R Mixer, 1.5 ml Block (Eppendorf). Samples were then 
incubated at 90⁰C for 60 minutes shaking at 600 rpm. Through the addition of 200 μl 
DNA Binding Buffer the DNA-content of the sample was bound to the filter 
compartment of the High Pure Filter Tube assembly which was then washed repeatedly. 
The purified, extracted DNA was eluted in 50 μl DNA Elution Buffer. 
From MPM cell lines genomic DNA was extracted using the DNeasy Blood and Tissue 
Kit (Quiagen) according to the manufacturers’ protocol. Briefly, cells were cultured in 
50 ml flasks with a growth surface of 25 cm2 until almost confluent. 3x106 cells were 
harvested, centrifuged and the pellet was resuspended in 200 μl PBS. Upon addition of 
20 μl Protein K and 200 μl Buffer AL the mixture was incubated for 10 minutes at 56 
ºC. After the addition of 200 μl absolute ethanol the mixture was pipetted in a DNeasy 
Mini spin column and centrifuged at 8000 rpm for 1 minute. The membrane of the 
comlumn was washed repeatedly using the wash buffers provided by the manufacturer 
and centrifuged. In the end, the extracted DNA was eluted from the DNeasy membrane 
to in 200 μl Buffer AE. 
The concentration and purity of the DNA was measured in a NanoDrop ND-1000 UV 
Visible Spectrophotometer (Thermo Scientific). 
The core TERT promoter region between the +65 and -278 bp from the ATG start site 
was amplified by PCR and screened using Sanger sequencing (Figure 20). The mutation 
analyses were performed by Prof. Rajiv Kumar’s group at the German Cancer Research 




Figure 20: Sequence and chromatograms show (A) wild-type TERT promoter,(B) a 
promoter region harboring a -57A>C mutation or (C) harboring a -124 C>T mutantion 
of the TERT promoter. Reprinted with permission of AACR from: [273] 
 
3.7 TERT mRNA expression 
 
Using TRIzol® Reagent® (Invitrogen) total RNA was extracted from 22 MPM cell 
lines and purified with Turbo DNase Kit (Ambion) according to the manufacturer’s 
protocol. From each sample a 2 μg amount of total RNA was reverse transcribed using 
High Capacity RNA-to-cDNA Kit kit (Applied Biosystems) according to the 
manufacturer’s protocol [277]. 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR was carried out 
using cDNA samples as templates, Maxima SYBR Green qPCR master mix (Thermo 
Scientific) and gene specific probes  in a C1000 Touch Thermal Cycler using the 
CFX96 Real-Time System (Biorad) [278]. The following gene specific probes were 
used: TERT fw (5ʹ-CCAAGTTCCTGCACTGG-3ʹ) and TERT rev (5ʹ-
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TTCCCGATGCTGCCTGAC-3ʹ); RPL41 fw (5ʹ-CAAGTGGAGGAAGAAGC-3ʹ) and 
RPL41 rev (5ʹ-TTACTTGGACCTCTGCCT-3ʹ). As endogenous reference RPL41 was 
used and fold changes were determined by ΔΔCt method [279]. 
 
3.8 Cell viability assay 
 
To characterize cellular sensitivity to cisplatin, we used Sulforhodamine B (SRB) assay. 
Briefly, cells were plated in the inner 60 wells of a 96-well plate. After 24hs cisplatin-
treatment with different drug concentrations (0, 0.5, 1, 3, 5, and 10 uM), cells were 
fixed with 10% trichloroacetic acid, which was followed by 15-minute staining with 
SRB. Excess dry was removed by repeated washing with 1% (vol/vol) acetic acid. After 
dissolving the protein-bound dye in 10 mM Tris OD at 570 nm was measured using a 
microplate reader (EL800, BioTec Instruments, Winooski, Vermont) [280]. 
 
3.9 Statistical analysis 
Associations between two categorical variables such as histopathologic characteristics, 
clinical parameters and TERT promoter status were calculated by Fisher’s exact test. 
Overall survival was defined as the time elapsed between the date of diagnosis and the 
date of death or date of last contact, and given in days. Overall survivals of subgroups 
within the study collectives were estimated using Kaplan-Meier method and differences 
between subgroup OS were computed by log-rank (Mantel-Cox) tests. Differences in 
hTERT mRNA expressions and in cisplatin sensitivity between TERT promoter wild-
type and mutant samples were analysed by two-tailed Student`s t test. To identify 
independent prognostic factors, multivariate Cox regression tests were performed and 
hazard ratios and corresponding 95% confidence intervals were calculated. Results were 
considered statistically significant if p<0.05, two-sided. Softwares GraphPad Prism 8.0 







4.1 Histologic grading and subtype analysis 
4.1.1 Clinicopathological characteristics of the patient collective 
 
Our study cohort consisted of 192 Central European patients, of whom 74.5% were 
male and 25.5% female patients. Their mean age was 65.0 years at the time of 
diagnosis. IMIG stage data was available for 126 patients, who had early stage disease 
and advanced stage disease in similar numbers (Table 6).  
 
Table 6: Clinicopathological characteristics of the MPM patient cohort. (NA= not 













age (years) mean ± SD 65.0 ± 10.8 
IMIG stage 
(NA = 66) 
I / II 






4.1.2 Histopathologic characteristics  
 
We analysed 192 MPM samples originally diagnosed as epithelioid type MPM. We 
classified these samples based on their predominant growth patterns. The most common 
subtype found among these epithelioid MPM samples was the solid pattern, accounting 
for 52.1% of all samples. Other common patterns were tubulopapillary accounting for 
28.6% and trabecular pattern identified in 10.4% of the samples. Microcystic, 
pleomorphic and micropapillary subtypes were rare, accounting for 4.7, 3.1 and 1.0%, 





Table 7. Histologic subtypes, nuclear grade and mitosis-necrosis score groups of the 











































































We performed histological grading of the samples using composit scores nuclear grade 
and mitosis-necrosis score. Nuclear grade was based on nuclear atypia and mitotic 
counts. Nuclear atypia was mild in 13 cases (6.7%), moderate in 132 cases (68.8%) and 
severe in 47 cases (24.5%). Mitotic count was low in 60.9%, intermediate in 21.4% and 
high in 17.7% of the cases. On calculating the scores based on these variables, 54.7% of 
the samples resulted nuclear grade 1, 32.3% nuclear grade 2 and 13.0% nuclear grade 3. 
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Necrosis was present in 49.0% of the samples and absent in 51.0%. Mitosis-necrosis 
score was calculated based on mitotic counts and the presence of necrosis. A mitosis-
necrosis score of 0 was assigned in 45.8% of the cases, while 40.1% of the cases was 
given mitosis-necrosis score 1 and 14.1% mitosis-necrosis score 3 (Table 7). 
 
4.1.3 Association between EMM subtypes and grade 
 
We found a significant association between solid and trabecular histologic subtypes and 
higher nuclear grades (p=0.0008, Chi-squared test) and mitosis-necrosis scores 
(p<0.0001, Chi-squared test) as visualized in Figure 21. 
 
 
Figure 21. Distribuiton of (A) mitosis-necrosis scores and (B) nuclear grades  among 
different EMM subtypes. [271] 
 
4.1.4 Histopathologic parameters and disease outcome 
 
We analyzed differnces in overall survival between histologic subtypes of EMM. Better 
prognosis was associated with the tubulopapillary and microcystic subtypes (median 
OS=727 and 936 days, respectively), while patients with a predominantly solid or 
trabecular pattern EMM had shorter median OS (397 and 394 days, respectively, Figure 
22 A). The shortest OS (173 days) was observed among patients with pleomorphic 
subtype EMM, which was significantly worse compared to tubulopapillary, microcystic 
and solid subtypes (p<0.0001, 0.0085 and 0.0277, respectively, Figure 22 A, Table 8).  
For further survival analyses we merged samples showing a predominantly microcystic 
pattern with tubulopapillary variants, as well as trabecular and solid pattern specimens, 
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because of the low frequencies of the microcystic and trabecular pattern and the 
pairwise overlapping survival curves. The pleomorphic variant was still included 
separately, because of its distinct dismal prognosis both in our study population and in 
literature data. (Figure 22 B, Table 8) Due to the low sample numbers, for tumors with 
micropapillary pattern (n=2), however, we were not able to calculate a median OS. 
Thus, we were not able to merge this subtype with any other patterns and these cases 
were excluded from further analysis.  
 
 
Figure 22. (A) Kaplan-Meier curves for solid, trabecular, tubulopapillary, microcystic 
and pleomorphic subtype EMM patients. (B) Survival curves of patients with 
pleomorphic, solid/trabecular or tubulopapillary/microcystic EMM. [271] 
 
Lumped solid/trabecular and tubulopapillary/microcystic subtype groups showed 
significantly different outcomes (median OS: 397 vs. 732 days, respectively, p=0.003, 
Figure 22 B, Table 8). 
We next analysed the associations between parameters of histological grading, composit 
grades and patient outcomes. On analysis of individual coponents of composit scores, 
we observed a significant difference in OS between subgroups exhibiting mild, 
moderate and severe nuclear atypia (median OS: 1197 days, 501 days [p=0.027] and 
306 days [p<0.001], respectively, Figure 23 A, Table 8). The presence of necrosis also 
associated with significantly shorter median survival (281 vs. 727 days, p<0.0001, 




Figure 23. Survival curves associated with individual parameters included in composit 
grading systems: (A) nuclear atypia, (B) mitotic count and (C) presence of necrosis. 
[271] 
 
We found that the composit histologic grading systems were able to predict patient 
outcomes. Significant survival differences were observed between patient subgroups 
with mitosis-necrosis scores 0, 1 and 2, median OS was 720 days, 383 days (p<0.0001) 
and 165 days (p<0.0001), respectively (Figure 24 A, Table 8). There was no significant 
difference between nuclear grade 1 and 2 patients median OS (555 days and 486 days, 
respectively, p=0.531), however, nuclear grade 3 was associated with significantly 
shorter median OS (123 days, p=0.0002, Figure 24 B, Table 8). 
In additional univariate analyses, we found that age or gender did not influence patient 
outcome, however, we identified significant differences among patient grouped by 

























































































































*NA, not available; SD, standard deviation; M/N, mitosis/necrosis; OS, overall survival, 




Figure 24 Patient outcomes associated with diferent histopathologic grading systems: 
(A) nuclear grading and (B) mitosis-necrosis score. [271] 
 
In multivariate analyses, the mitosis-necrosis score was the single independent 
prognostic factor among the histopathologic variables investigated (Table 9). 
 
Table 9. Multivariate Cox regression analysis in the MPM patient cohort. [271] 
 
Multivariate analysis 
HR 95% CI p-value 
Histology  solid/trabecular 
tubulopap./microcyst. 












1.08 0.78-1.48 0.648 
*CI, confidence interval; HR, hazard ratio; tubulopap., tubulopapillary; microcyst., 
microcystic; M/N, mitosis/necrosis. 
 
4.1.5 Histopathologic parameters in the validation cohort 
 
The validation cohort (Table 10) consisting of 55 patients included in the TCGA 
mesothelioma collection exhibited similar male to female ratio (76.4% to 23.6%), while 
patients mean age was lower (60.3 years) and the ratio of advanced stage disease 
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patients was higher (69.1% vs 30.9%) than in the study collective. In the validation 
cohort we identified the tubulopapillary and solid subtypes as most common patterns 
(50.9% and 30.9%, respectively), while micropapillary, trabecular and microcystic 
patterns occurred with a relatively low frequency (7.3%, 5.5% and 5.5%, respectively). 
Since both composit grading systems require assessment of fine morphological 
characteristics such as mitotic count and nuclear atypia, histological grading was only 
carried out on FFPE specimens (n=49) and was omitted in cases where only fresh 
frozen sections were available (n=6). Nuclear grade 1, 2 and 3 samples were identified 
in 34.5% 47.3% and 7.3%, while mitosis-necrosis score 0, 1 and 2 were assigned in 
41.8%, 36.4% and 10.9% of the cases. 
 













Age (years) mean ± SD 60.3 ± 10.2  
IMIG stage 
(NA = 66) 
I / II 



















































In concordance with our findings in the study cohort, we found a significant association 
between high histologic grades and solid/trabecular growth patterns (Figure 25). 
 
 
Figure 25. Distribution of (A) nuclear grades 1-3 and (B) mitosis-necrosis scores 0-2 
among histologic variants of epithelioid mesothelioma. [271] 
 
In order to allow better comparison between our study cohort and the validation cohort, 
we merged solid and trabecular, as well as tubulopapillary and microcystic predominant 
pattern subgroups for survival analyses. In univariate analysis we observed a 
significantly worse median OS associated with solid/trabecular growth patterns (406 vs. 
795 days, respectively, p=0.01, Figure 26, Table 12),  
 
 
Figure 26. Kaplan-Meier curves for solid/trabecular and tubulopapillary/microcystic 
predominant pattern MPM in the TCGA cohort. [271] 
 
Patients with nuclear grade 3 tumors had a significantly shorter median OS, than those 
with lower grade tumors (232 days vs. 823 and 459 days, respectively, Figure 27 B, 
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Table 12), and the same association was seen for mitosis-necrosis score 2 tumors (330 
days vs. 795 and 511 days in M/Nscores 0 and 1, respectively Figure 27 A, Table 11). 
 
Figure 27. Survival curves for mitosis-necrosis scores (A) and nuclear grades (B). 
[271] 
 





































































*CI, confidence interval; HR, hazard ratio; M/N, mitosis/necrosis; IMIG, International 




The relatively small sample number of the validation cohort limited the feasibility of a 
multivariate analysis.  
 
4.1.6 Histological subtypes and disease stage 
We analysed the prognostic impact of histological subtypes within subcohorts of 
patients with early stage (IMIG I/II) or advanced (IMIG III/IV) diseases. In advanced 
stage disease we found a significant difference in overall survival between the two 
histologic subtypes (p=0.047, Mantel-Cox regression, Figure 28 B). In early stage cases 
the difference between the OS of the two histologic subtype groups proved significant 
by Gehan-Breslow-Wilcoxon (p=0.041) which is more sensitive for early events. Of 
note, using the Mantel-Cox regression analysis, the difference was not significant 
(p=0.194) due to a cross-over at the tails of the curves (Figure 28 A). We found that the 
solid/trabecular and tubulopapillary/microcystic histologic subtypes were evenly 
distributed among early and advanced stages (p=0.999, Fisher’s exact test, Figure 28 C). 
 
Figure 28. Survival curves of lumped groups of solid/trabecular and 
tubulopapillary/microcystic among early stage patients (A) and late stage patients (B). 




4.1.7 Differences in response to MMT among EMM subtypes 
To assess association of treatment with epithelioid MPM subtypes, we analysed the 
correlations and OS data in the subcohort with available treatment information (n=109). 
 
Table 12: Therapeutic regimens received by the patients in our exploratory subcohort. 
[271] 
Treatment modalities 109 patients 
Multimodal therapy 44 
         EPP + platinum/pemetrexed + IMRT 18 
         Surgery + chemotherapy  25 
- EPP + platinum/pemetrexed 10 
- eP/D + platinum/pemetrexed 8 
- EPP+ platinum/gemcitabine 4 
- eP/D + platinum 1 
- unspecified MCR surgery + platinum/taxane 1 
- unspecified MCR surgery + 
platinum/epirubicine 
1 
         EPP + radiation therapy 1 
Non-multimodal therapy 65 
         Chemotherapy 44 
- platinum/pemetrexed 28 
- platinum/gemcitabine 6 
- platinum/cyclophosphamide/epirubicine 3 
- platinum/bortezomib 2 
- pemetrexed 1 
- unspecified chemotherapy 4 
        Radiotherapy 1 
        Chemotherapy + radiotherapy 1 
        Surgery 5 
- EPP 3 
- unspecified surgery 2 
        Best supportive care 14 
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In this subcohort, 59.6% (65/109) did not receive multimodal therapy. Among these 
patients 44 (40.4%) received chemotherapy, 5 (4.6%) surgery only, 1 (0.9%) 
radiotherapy only, 1 (0.9%) chemoradiotherapy. 40.4% of the patient (44/109) received 
multimodal therapy which included macroscopic total resection of the tumor in 
combination with chemoradiotherapy (Table 12).  
Between the two compared subgroups solid/trabecular and tubulopapillary/microcystic 
tumor growth patterns we found no significant difference in the contingency neither in 
patients’ age, gender, disease stage nor histopathologic grades of tumors among patiets 
who received MMT. Among patients who did not receive MMT, 
tubulopapillary/microcystic tumors were significantly associated with lower nuclear 









We grouped patients into four subgroups based on tumor histologic subtype 
(solid/trabecular or tubulopapillary/microcystic) and the treatment received (MMT or 
non-MMT). Interestingly, we were able to identify a tendency for better patient 
outcomes associated with tubulopapillary/microcystic patterns in contrast to 
solid/trabecular subtypes within the MMT subgroup (1068 versus 580 days, HR: 2.29 
[95% CI: 0.95-5.12], p=0.066, Figure 29). MMT provided a significant benefit within 
both  tubulopapillary/microcystic and solid/trabecular patterns, compared to a non-
MMT approach, however, the difference was more pronounced in the 
tubulopapillary/microcystic predominant subtype (MMT versus non-MMT within the 
tubulopapillary/microcystic patterns: 1068 vs. 406 days, HR: 2.67 [95% CI: 2.18-3.08], 
p=0.0006; MMT versus non-MMT within the solid/trabecular variants: 580 vs. 327 
days, HR: 1.77 [95% CI: 1.24-2.31], p=0.0018). There was no significant difference in 
patient outcomes among the histologic subtypes among patients who did not receive 
MMT (tubulopapillary/microcystic: median OS=406 days, solid/trabecular: 327 days, 
HR=1.16 [95%CI: 0.65-2.07], p=0.617). 
 
 
Figure 29. Kaplan-Meier curves of solid/trabecular and tubulopapillary/microcystic 
variants among patients who received multimodal therapy (MMT) or a non-multimodal 




4.2 TERT promoter mutation 
 
4.2.1 TERT promoter mutation and clinicopathological characteristics 
We analysed 182 MPM cases including 69.8% epithelioid, 24.2% biphasic and 4.9% 
sarcomatoid histologies. The male to female ratio was 3.7 (78.6% and 21.4%, 
respectively). 29.7% of the patients were diagnosed at stage I/II and 47.3% at stage 
III/IV disease, IMIG stage was not available in 42 cases (23.1%). Karnofsky 
performance status was available in 167 cases, 83.8% (n=140) of whom were able to 
carry on normal activity with no or only some symptoms at the time of diagnosis. 
EORTC prognostic score was available in 140 cases and estimated a poor prognosis in 
71.4% (n=100) of these patients (Table 14). 
 
Table 14. Clinicopathological characteristics of MPM patients grouped based on TERT 
promoter mutation status and their associations estimated by Fisher’s exact test. 
Reprinted with the permission of AACR from: [273] 
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We found TERT promoter mutations in 10.4% of all samples (19/182). The mutations 
were detected at higher frequencies among non-epithelioid types than in epithelioid 
samples (22% and 5.5%, respectively). The association between non-epithelioid 
histologic types and TERT promoter mutant status was statistically significant 
(p<0.001). All of the identified TERT promoter mutant cases were diagnosed at an 
advanced stage (p=0.002, Table 13). Among the 19 TERT promoter mutant MPM 
samples 13 (68.4%) harbored the -124 C>T mutation. We detected the -146 C>T 
mutation in 2 (10.5%) cases and the -57 A>C mutation in 4 (21.0%). 
We divided our cohort into a test cohort consisting of our Austrian patient collective 
(n=83, Table 15) and a validation cohort of the Slovenian and Croatian patients (n=99, 
Table 16).  
 
Table 15. Clinicopathological characteristics in the Austrian patient collective and their 
distribution among TERT promoter wild-type and mutant cases. Reprinted with the 
permission of AACR from: [273] 

















Age (years) mean ± SD 
61.8  
± 1.3  
61.7  
± 1.4 
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(NA = 24) 
I / II 






















Similarly to the merged cohort we found a significant association between non-
epithelioid subtype and TERT promoter mutant status (p<0.001 in the test cohort and 
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p=0.041 in the validation cohort). A significant association between the mutant status 
and advanced IMIG stage was only observed in the validation cohort (p=0.026). TERT 
promoter mutation was not associated with gender, age, performance and prognostic 
scores in either of the cohorts. 
 
Table 16. Clinicopathological characteristics of the Slovenian-Croatian validation 
cohort grouped based on TERT promoter status. Reprinted with the permission of 
AACR from: [273] 















Age (years) Mean ± SD 66.2  









































(NA = 18) 
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4.2.2 TERT promoter mutation and histological subtypes of epitheioid MPM 
 
We also investigated the TERT promoter mutations’ distribution among 109 epithelioid 
samples exhibiting different predominant growth patterns (Table 17). No significant 
association to TERT promoter status was identified among the solid, trabecular, 
tubulopapillary, microcystic and micropapillary patterns (p=0.75). Pleomorphic pattern 
EMM samples exhibited a TERT promoter mutation frequency similar to that of the 
non-epithelioid MPMs (33.3% and 22%, respectively), and in comparison to non-
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pleomorphic epithelioid MPM samples, the pleomorphic pattern was significantly 
associated with more frequent TERT promoter mutations (p=0.035). 
 
Table 17. TERT promoter mutations in histologic subtypes of epithelioid MPM. 










Solid 44 43 1 
0.875* 
Trabecular 10 9 1 
Tubulopapillary 40 38 2 
Microcystic 8 8 0 
Micropapillary 1 1 0 
Pleomorphic 6 4 2 
0.035** 
Non-pleomorphic 103 99 4 
*: Chi- squared test, **: Fisher’s exact test 
 
4.2.3 TERT promoter mutation and BAP1 expression  
 
We performed BAP1 immunohistochemical staining on 75 samples. Loss of nuclear 
BAP1 staining was observed at a frequency in line with the literature and was 
significantly associated with epithelioid type MPM (p=0.023, Table 18).  
 
Table 18. BAP1 expression among the three main histologic types. Reprinted with the 
permission of AACR from: [273] 
 Total (n= 75) BAP1 + BAP1 – p-value 
Histology     
Epithelioid 55 21 (38.2%) 34 (61.8%) 
0.023* Biphasic 15 6 (40.0%) 9 (60.0%) 
Sarcomatoid 5 5 (100%) 0 (0%) 
TERT promoter     
Mutant 9 9 0 
0.0002** 
Wild-type 66 22 44 




Strikingly, we found a strong correlation between TERT promoter mutant status and 
retained BAP1 expression (p=0.0002). Among all TERT promoter mutant samples, each 
exhibited a retained nuclear BAP1 expression, thus we found that the TERT promoter 
mutation and the loss of BAP1 were mutually exclusive in our cohort (Table 18). 
 
4.2.4 TERT promoter status and patient outcomes 
 
The prognostic impact of TERT promoter mutations was analysed by Kaplan-Meier 
method. Among the 182 cases of the entire patient collective, TERT promoter mutant 
status was associated with a significantly worse median OS when compared to TERT 
promoter wild-type samples (262 vs. 469 days, p<0.0001, Figure 30 A). The prognostic 
impact was also found when analyzing the Austrian and the Croatian-Slovenian patient 
collectives separately. In the Austrian cohort the TERT mutant subgroup had a 262-day 
median OS, while the wild-type subgroup’s median OS was 524 days (p=0.0012, Figure 
30 C). In the Croatian-Slovenian subcohort, where the difference in survival was also 
significant between TERT promoter mutant and wild-type cases (104 vs. 465 days, 
respectively, p=0.0024, Figure 30 D).  
Histologic types of MPM are known to have a strong prognostic impact on OS, which 
was also confirmed in our study: patients with epithelioid type tumors had a 
significantly longer OS compared to those with non-epithelioid tumors (459 days vs. 
353 days, p=0.01, Figure 30 B). Since the TERT promoter mutant status was 
significantly associated with non-epithelioid histologic type, we analysed the impact of 
TERT promoter mutations among epithelioid and non-epithelioid MPM cases 
separately. The significant negative prognostic effect of TERT promoter mutant status 
was identified in both histologic subgroups, median OS of mutant and wild-type tumors 
was 340 and 510 days among the epithelioid subgroup, and 199 days vs. 412 days 




Figure 30. TERT promoter status and histologic type both have a significant impact on 
patient outcomes (OS). Kaplan-Meier curves for the entire cohort grouped by: (A) 
TERT promoter mutant or wild-type status, (B) epithelioid and non-epithelioid 
histologic types. Overall survival and TERT promoter status: (C) in the Austrian patient 
collective and (D) in the Croatian plus Slovenian validation cohort, (E) among all 
epithelioid histotype MPM cases and (F) all non-epithelioid MPM cases. Reprinted with 




In univariate analyses, epithelioid and non-epithelioid histologic types, Karnofsky 
performance status, EORTC prognostic score, IMIG stage and the presence of TERT 
promoter mutations all had a significant prognostic impact (Table 19). 
 
Table 19. Univariate analyses of clinicopathological variables in all MPM patients. P-
values calculated by log-rank test. Reprinted with the permission of AACR from: [273]. 
    


















































In multivariate analyses we found that TERT promoter status and main histologic types 
were independent prognostic factors (p=0.011 and p=0.009, respectively, Table 20).  
 
Table 20. Multivariate analyses of clinicopathological factors influencing OS. 
Reprinted with the permission of AACR from: [273] 
  
HR 95% CI p-value 
Gender  male 
 female 
0.923 0.580-1.470 0.737 
 
Age (years) <70 
70 




0.563 0.366-0.867 0.009 
IMIG stage early (I/II)  
late (III/IV) 





0.427 0.220-0.826 0.011 
 
The TERT promoter mutant status was found to be also an independent prognostic 
factor in a multivariate analysis that included the EORTC prognostic score (Table 21). 
 
Table 21. Multivariate analysis of clinical prognostic factors and TERT promoter status 
influencing disease outcome. Reprinted with the permission of AACR from: [273] 
 
    
HR 95% CI p-value 
Age (years) <70 
70  
0.942 0.599-1.482 0.797 
EORTC 
Prognostic Score  
1.27 
>1.27 
0.545 0.333-0.894 0.016 
IMIG stage early (I/II) 
late (III/IV) 
0.732 0.466-1.150 0.175 
TERTp status TERTpwt 
TERTpmut 
0.392 0.179-0.858 0.019 
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4.2.5 Patient outcomes and SNP rs2853669 
 
Data on the rs2853669 SNP carrier status was available on 121 cases, of which 5.8% 
were TERT promoter mutant and carriers of the common polymorphism (7/121), 6.6% 
mutants and non-carriers (8/121), 47.1% TERT promoter wild-type and non-carriers 
(57/121) and 40.5% wild-type and SNP carriers (49/121). Median OS of the four groups 
were 200 days, 257 days, 622 days and 490 days, respectively. There was no significant 
difference between carriers and non-carriers among TERT promoter mutatns (p=0.935), 
thus, the presence of the SNP did not eliminate the negative prognostic impact of the 
promoter mutations (Figure 31). 
 
 
Figure 31. Kaplan-Meier curves of patients subgroups carrying and not carrying the 
common polymorphism rs2853669 with and without TERT promoter mutations. 
 
4.2.6 TERT mRNA expression and TERT promoter status 
 
We analysed mRNA expression of the hTERT gene in 22 de novo established MPM 
cell lines by quantitative PCR. Among the 22 cell lines, 7 harbored -124C>T and 2 -
57A>C mutation of the TERT promoter region, while 13 were TERTp wild-type. We 
identified a significant difference in the hTERT expression of TERT promoter mutant 




Figure 32. TERT mRNA expression relative to expression of housekeeping gene RPL41 
is significantly different in cell lines harboring TERT promoter mutations (n=9) and 
TERT promoter wild-type cell lines (n=13). Reprinted with the permission of AACR 
from: [273] 
 
4.2.7 TERT promoter status and cell line formation 
 
To further investigate the mechanisms underlying the TERT promoter mutations 
negative impact on patient outcomes, we compared the ability of 45 MPM tumor 
samples to form de novo cell cultures based on our experience between 2009 and 2016. 
Of 45 primary cell cultures, 22 cell lines were successfully established (48.9%). We 
found that successful in vitro cell line formation was associated with shorter median OS 
(268.5 days vs. 607 days, p<0.001, Figure 33 A) Of the 22 immortalized tumor cell 
lines 9 harbored TERT promoter mutations, while neither of the 23 cultures that failed 
to undergo immortalization did harbor any of these non-coding mutations. Thus, TERT 
promoter mutant status was significantly associated with cell line formation (Figure 33 
B, p<0.001), while IMIG stage of the original tumor or non-epithelioid histology did not 






Figure 33. (A) Successful cell line formation conferred a significant negative impact on 
patient outcomes (p=0.0008). (B) Tumors harboring a TERT promoter mutation were 
significantly more likely to be immortalized (p<0.001). (C) Original tumors’ histologic 
type and (D) stage at the time of diagnosis did not have a significant impact on cell line 
formation. Reprinted with the permission of AACR from: [273] 
 
4.2.8 TERT promoter status and in vitro cisplatin sensitivity 
 
To assess the impact of TERT promoter status on cisplatin sensitivity in MPM, we used 
24 cell MPM cell lines, 5 of them international cell lines and 19 de novo cell lines and 
carried out SRB assays to determine their IC50 values for cisplatin. 7 of the cell lines 
harbored a TERT promoter mutation, while 17 were TERT promoter wild-type. We did 
not find a statistically significant difference in cisplatin sensitivity, however we 
observed that cell lines harboring TERT promoter mutations showed a tendency to have 




Figure 34: A tendency for lower IC50 values for cisplatin was observed in the seven cell 
lines harboring a TERT promoter mutation in comparison to seventeen TERTp wild-







5.1 Histologic subtypes of epithelioid mesothelioma 
 
Of the three main histologic types – epithelioid, biphasic and sarcomatoid – of MPM, 
epithelioid histology is associated with the longest median overall survival; however, 
median OS shows a wide variability among these cases. Patients with EMM are the 
most likely to be eligible for a more aggressive therapy consisting of macroscopic 
complete resection of the tumor and adjuvant chemo- and/or radiotherapy [91]. The 
multimodal treatment approach is, however, associated with numerous serious 
complications, and less than half of the patients are able to complete the MMT 
protocols, in part because of complications, in part because of progression during 
treatment. Taking all these into account, there is an urgent need for both prognostic and 
predictive factors that help identify patients most likely to benefit from multimodality 
treatment among EMM cases. 
Histologic subtyping of EMM is a promising prognostic factor according to previous 
studies. However, data is only available on retrospective cohorts of limited size due to 
the rarity of the disease (Table 22). The studies available at this time show substantial 
variability among the different subtypes, however, in each of them solid and 
tubulopapillary subtypes occurred at the highest frequencies, while other growth 
patterns were relatively rare. The prognostic impact of most subtypes remains unclear. It 
is only the pleomorphic subtype which was found to be an independent prognostic 
factor in multivariate analyses [94]. The solid pattern compared to all non-solid 
subtypes was associated with shorter median OS, however not independently associated 
with OS [120]. 
To the best of our knowledge, our investigation provides data on EMM subtyping in 
context of patient outcomes on the second largest cohort published until this date. No 
definitve finding on the prognostic impact on the subtypes was provided, however, we 
found growth pattern analysis to be a promising histopathologic factor which can be 





Table 22. Summary of results from studies investigating patient outcomes and histologic 
subtypes of EMM. 
Study  
(No. of samples) 
Subtypes 
analysed 




Kadota et al. [94] Solid 38% 13.7 (10.0–16.9) 0.020 
(232) Tubulopapillary 22% 17.9 (14.4–32.5) 0.002 
Trabecular 16% 24.9 (22.9–39.9) <0.001 
Pleomorphic 15% 8.1 (4.9–17.0) Ref. 
Micropapillary 9% 15.8 (9.3–45.3) 0.021 
Brčić et al. [121] Solid 45% NA NA 
(98) Tubulopapillary 19% NA NA 
Acinar 18.4% NA NA 
Adenomatoid 6% NA NA 
Pleomorphic 5% NA NA 
 Micropapillary 2% NA NA 
Alchami et al. [119] Tubulopapillary 43% 17 (15.1-18.9) 0.084 
(112) Solid 29% 14 (9.4-18.6) 0.040 
Microcystic/ 
myxoid 
14% 24 (16.2-32.8) Ref. 
Pleomorphic 9% 8 (6.0-10.0) <0.001 
Micropapillary 5% 12 (7.2-16.8) 0.008 
Bilecz et al. [271] Solid 52% 13.2   
(182) Tubulopapillary 29% 24.2  
Trabecular 10% 13.1  
Microcystic 5% 31.2  
Pleomorphic 3% 8.0  





5.2 Pleomorphic subtype EMM confers dismal prognosis 
 
There is consensus on the negative prognostic effect of EMM with pleomorphic 
features, which is an independent prognostic factor in multivariate analyses [94]. It was 
proposed to be reclassified as non-epithelioid MPM; however, it was not implemented 
by the most recent WHO classification of MPM. We provided data supporting previous 
findings on dismal prognosis associated with pleomorphic EMM.  
We also found that pleomorphic feature tumors harbored TERT promoter mutations at a 
high frequency similar to that of non-epithelioid MPM, providing a compelling 
molecular pathomechanism that explains the aggressive clinical behavior of 
pleomorphic MPM. 
 
5.3 Histopathologic grading systems are robust prognostic factors in EMM 
 
Until recently, there was no established histologic grading of EMM. Nuclear grading is 
the most widely accepted method, however, still not included as mandatory part of 
MPM pathologic reporting. The mitosis-necrosis score showed similar prognostic 
power to that of the nuclear grading and was based on easier-to-assess histologic 
variables. We were able to confirm the prognostic value of both grading systems, 
however, the mitosis-necrosis score was a more robust prognosticator of EMM 
outcomes in our cohort. In concordance with our findings, the 2019 EURACAN/ISLC 
proposal also recommends the use of a two-trier grading system for MPM. We found a 
significant association between high histologic grades and solid/trabecular predominant 
growth patterns of the EMM samples. 
 
5.4 Histologic subtyping and predicting patients’ benefit from MMT  
 
There are no established predictive factors that identify patients who are most likely to 
benefit from MMT. So far localized disease stage, young age and epithelioid histology 
were used to select patients for aggressive surgical treatment and chemoradiotherapy. 
Blood CRP levels are emerging biomarkers that are likely to be predictive in this 
clinical setting [281]. In lung adenocarcinomas, there is substantial evidence that 
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histologic assessment of predominant growth patterns predicts patient subgroups 
showing more pronounced treatment response than other histologic subtypes.  
Histological biopsy samples are available in almost all MPM cases. We evaluated if 
histologic subtyping of HE stained sections of small biopsies would be of help to 
identify patient subgroups with favorable responses to multimodal treatment in an 
explorative subcohort analysis. We formed patient subgroups based on therapy received 
(MMT or no MMT) and tumor histology (lumped groups solid/trabecular or 
tubulopapillary/microcystic). The subgroups that received MMT were comparable 
regarding patients’ age, gender and tumor grade distribution. Interestingly, we found a 
borderline significant difference in patient outcomes between the solid/trabecular and 
tubulopapillary/microcystic patterns, the latter being associated with longer OS after 
MMT. These findings might be an exciting path for further investigation; however, their 
feasibility is limited by the size and the retrospective nature of our study and needs 
independent confirmation. 
 
5.5 TERT promoter mutation is an independent negative prognostic factor in malignant 
pleural mesothelioma 
 
TERT promoter mutation is associated with shorter median OS in a variety of tumor 
types, e. g. in gliomas, cutaneous malignant melanoma or bladder cancer. In a previous 
study, these non-coding mutations were associated with shorter median OS and with 
sarcomatoid histologic type and caused hTERT overexpression [282]. Recently, the 
negative prognostic role of TERT promoter mutation has been recapitulated and ´this 
mutation was found to be the third most common genetic alteration in MPM [190]. 
We were able to confirm the TERT promoter mutation as an independent negative 
prognostic factor. This prognostic impact was demonstrated both in epithelioid as well 
as in non-epithelioid cases. The difference in OS was independent of geographic 
differences, too, being present in both the Austrian and the Croatian-Slovenian 





5.6 TERT promoter mutation and implications in systemic treatment for MPM 
 
Reverse transcriptase inhibitors have long been used in the setting of AIDS treatment 
with tolerable toxicities and telomerase inhibitors have previously been tested as 
anticancer agents [283, 284]. The failure of previous studies might be attributable to 
ineffective inclusion criteria. Although telomerase activity or alternative telomere 
lengthening can be proven in most malignancies, the TERT promoter mutations leading 
to TERT overexpression represent a distinctive therapeutic target. We identified that 
approximately 10% of MPMs carry the quasi oncogenic mutation in the TERT promoter 
region which might be a marker for telomerase inhibitor efficacy. 
First line systemic therapy of MPM is platinum based in combination with antifolate 
agents. The efficacy of these treatments is, however, dissatisfactory: most patients 
experience serious side effects and disease progression during therapy or recurrence 
after that. To evaluate the TERT promoter mutations' interaction with cisplatin 
sensitivity we carried out viability assays at various cisplatin concentrations in cell 
cultures. Interestingly, we found increased sensitivity for cisplatin in cell lines harboring 
TERT promoter mutations. The potential predictive role of TERT promoter mutations 
has been reported in gliomas where the mutant status was associated with response to 
adjuvant radiotherapy and alkylating agents [285]. Furthermore, TERT promoter 
mutation was found to predict response to eribulin mesylate, an agent reversing 
epithelial-mesenchymal transition in cell lines derived from ovarian malignancies [286]. 
In poorly differentiated thyroid carcinomas TERT promoter mutations were associated 
with radioidine resistance [287].  
 
5.7 Mechanism of increased aggressivity of TERT promoter mutant MPM 
 
TERT promoter mutations occur more frequently in MPM derived cell lines in 
comparison to FFPE MPM tumor specimens. Previously, this was explained by the 
higher sensitivity of the mutation detection in tumor cell lines [249]. We offer a 
different explanation for this finding, thus, that harboring TERT promoter mutations 
promote cell line formation. We observed that among 45 primary cell cultures all those 
originating from tumors harboring a promoter mutation were successfully immortalized, 
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and the TERT promoter mutation frequency was 41% among cell lines. In contrast, cell 
line formation was not associated with the histologic type and tumor stage at the time of 
the diagnosis and was only moderately associated with pleomorphic features in the 
original tumor samples.  
 
5.8 Impact of the SNP rs2853669 in mesothelioma 
 
The polymorphism rs2853669 C>T is known to quenche the negative prognostic effect 
associated with TERT promoter mutations in bladder cancer [258], diffuse gliomas  and 
primary glioblastoma [264-266]. We compared patient outcomes among four 
subgroups: harboring TERT promoter mutations with or without variant allels of the 
SNP and TERT promoter wild type patients with or without the variant allele. We did 
not observe any difference between subgroups differing in the SNP status. Thus, the 
quenching effect of the variant allele seen in other cancer types was not confirmed in 
our MPM cohort. 
 
5.9 Association of major molecular alterations and TERT promoter mutation 
 
Nuclear reactivity of BAP1 immunohistochemical staining is known to correlate with 
retained expression of the BAP1 gene and the intact functionality of the protein product.  
In our subcohort consisting of 75 MPM samples we observed that each TERT promoter 
mutant sample exhibited nuclear immunohistochemical reactivity for BAP1, while the 
loss of nuclear BAP1 staining only occurred in TERT promoter wild-type samples. 
Thus, we concluded that loss-of function mutations and deletions of the BAP1 gene 
were mutually exclusive with the TERT promoter mutations. This finding is in line with 





Reflecting on the aims of the present study and summarizing our results, we were able 
to draw the following conclusions: 
 
1. We found that the microcystic and tubulopapillary subtypes of epithelioid 
mesothelioma associated with the longest median overall survival, while the 
solid and trabecular variants with shorter OS. Our data supports the proposal to 
consider the pleomorphic subtype in terms of prognosis as sarcomatoid MPM. 
We found an association between higher histological grades and solid/trabecular 
subtypes. Both the nuclear grading system and mitosis-necrosis score was useful 
in predicting patient outcomes, however, the mitosis score composed of two-tier 
factors (mitoses low vs. high, necrosis present vs. absent) was more robust in 
our experience. 
 
2. We found a more pronounced benefit from a multimodal treatment approach in 
patients with tubulopapillary/microcystic subtype tumors compared to 
solid/trabecular tumors. 
 
3. TERT promoter mutant status was a strong, independent predictor of poor 
prognosis. The difference in OS remained significant both within histologic 
types (epithelioid and non-epithelioid) and in geographically different 
subcohorts. We found that the mutant status was strongly associated with non-
epithelioid histological type and the pleomorphic subtype of EMM. 
 
4. We found that the common polymorphism rs2853669 C>T – in contrast to 
literature data on bladder cancer and primary glioblastoma – did not show any 
interaction with the TERT promoter mutation in MPM, and the effect of TERT 





5. The probability of de novo cell line formation was significantly higher in TERT 
promoter mutant MPM samples. TERT mRNA expression was significantly 
higher among cell lines harboring a TERTp mutation. We observed a tendency 
of higher in vitro cisplatin sensitivity among cell lines with mutant TERT core 
promoter region in comparison to TERTp wild-type cell lines. 
 
6. In our MPM cohort mutations of the TERT core promoter region and genetic 






Az MPM ritka, ám rendkívül rossz prognózisú betegség. Megelőzését szolgálja az 
azbeszthasználat tilalma, azonban a közeljővőben nem várható az MPM incidenciájának 
jelentős csökkenése világszerte. A jelenlegi kezelési módok nem eredményeznek 
jelentős javulást a betegek túlélésében és a terápiás választ előrejelző faktorok sem 
ismertek. Így célul tűztük ki, hogy klinikailag alkalmazható, prognosztikus és prediktív 
szövettani és molekuláris faktorokat azonosítsunk. 192 epithelioid MPM esetet és az 
ezekhez kapcsolódó klinikai adatokat gyűjtöttünk öt nagy európai mellkassebészeti 
centrumból, majd a mintákat szövettani növekedési mintázat és grádus szempontjából 
vizsgáltuk HE festett metszeteken. Az EMM szövettani altípusai és a betegek túlélése 
között jelentős összefüggést találtunk, ezen belül a pleomorph altípus járt a legrosszabb 
prognózissal. A szolid/trabekuláris altípusok között nagyobb számban voltak magas 
magi grádusúak. Mind a magi jellemzők, mind a mitozisszám és nekrózis megítélésére 
épülő grade-rendszer jelentős prognosztikus erővel bírt. A trimodális kezelésben 
részesült betegek két jelentősen eltérő túlélésű csoportra voltak bonthatóak a tumoraik 
szolid/trabekuláris vagy tubulopapilláris/mikrocisztikus növekedési mintázata alapján. 
182 epithelioid és nem-epithelioid MPM szövetminta és 22 MPM eredetű sejtvonal 
esetében a TERT promoter (TERTp) mutációs státuszát határoztuk meg. Az esetek 
10.4%-ában azonosítottunk mutációt. A mutáns státusz a betegek túlélését 
kedvezőtlenül befolyásoló független prognosztikus faktornak bizonyult. 75 minta 
esetében BAP1 elleni antitesttel immunhisztokémiai reakciót végztünk, és a BAP1-
vesztés valamint a TERTp mutációk egymás kizáró voltát azonosítottuk. Primer 
sejtkultúrákat hoztunk létre 45 beteg mintájából, melynek során a sejtvonal létrehozás 
sikere és a TERTp mutáns státusz között szignifikáns összefüggést találtunk. Az 
elvégzett qPCR vizsgálatok alapján a mutáns státusz fokozott mRNS-expresszióval járt. 
Sejtvonalak életképességét különböző ciszplatin koncentrációjú médiumban vizsgálva a 
TERTp mutáns sejtvonalak ciszplatinnal szembeni fokozott érzékenységét figyeltük 
meg. Összefoglalva, eredményeink alapján az EMM szövettani típusai és szövettani 
gradálása prognosztikus és prediktív jelentőségű, így a patológiai leletek fontos része 
lehet. A TERT promoter mutációi az MPM új molekuláris csoportját definiálják és 





Malignant pleural mesothelioma (MPM) is a rare disease with dismal prognosis. 
Although there are efforts to prevent MPM mostly through government bans on 
asbestos production and use, its worldwide incidence is not expected to diminish soon. 
The treatment options available for MPM patients fail to achieve long-term survival and 
there is an urgent need for predictive biomarkers. Therefore, we aimed to identify 
molecular and histological prognostic and predictive factors that can be employed in the 
clinical setting. We collected 192 epithelioid MPM (EMM) samples and corresponding 
clinical data from five large European thoracic oncology centers. Next, we evaluated the 
histological subtypes and performed grading on HE stained sections. We found 
histological subtypes of EMM to have significant prognostic impact, and we confirmed 
the dismal prognosis associated with the pleomorphic subtype. The solid/trabecular 
patterns were associated with higher nuclear grades. Both the nuclear grading system 
and the mitosis-necrosis score showed significant prognostic power. Among patients 
who received a more aggressive, multimodal treatment those with 
tubulopapillary/microcystic subtype tumors showed a borderline significant tendency 
for more pronounced improvement in median OS. We also tested 182 samples including 
both epithelioid and non-epithelioid cases, as well as 22 novel patient-derived MPM cell 
lines for TERT promoter mutation. Mutations were found in 10.4% of the cases. The 
promoter mutations significantly associated with poor patient outcomes and were found 
to be an independent prognostic factor. Through BAP1 immunohistochemistry on 75 
specimens we found TERT promoter mutation and BAP1 loss to be mutually exclusive 
genetic alterations. Primary cell cultures were established in 45 patients and TERT 
promoter mutation conferred an increased probability of de novo cell line formation. 
Harboring a promoter mutation led to significant increase in TERT mRNA expression 
as quantified by qPCR in our 22 MPM cell lines. By measuring cell viability following 
cisplatin treatment we found increased cisplatin sensitivity in TERT promoter mutant 
cells. In conclusion, we provided data supporting the inclusion of histological subtypes 
and histological grading in pathological reporting on epithelioid MPM due to their 
prognostic and potentially predictive role. TERT promoter mutations independently 
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